<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INTELENCE - etravirine tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use INTELENCE<span class="Sup">®</span> safely and effectively. See full prescribing information for INTELENCE<span class="Sup">®</span>.<br> <br>INTELENCE<span class="Sup">®</span> (etravirine) tablets for oral use<br> <br>Initial U.S. Approval 2008</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="if78eb305-96fa-429d-8cbc-02c11b53b41f"></a><table class="Noautorules" width="70%">
<col align="left" valign="top" width="80%">
<col align="left" valign="top" width="20%">
<tbody class="Headless">
<tr>
<td align="left">Indications and Usage (<a href="#S1">1</a>)</td>
<td align="left">3/2012</td>
</tr>
<tr>
<td align="left">Dosage and Administration</td>
<td align="left">3/2012</td>
</tr>
<tr>
<td align="left">  Children and Adolescents (<a href="#S2.2">2.2</a>)</td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  Method of Administration (<a href="#S2.3">2.3</a>)</td>
<td align="left"></td>
</tr>
<tr>
<td align="left">Warnings and Precautions</td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> (<a href="#s5.3">5.3</a>)</td>
<td align="left">8/2012</td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">INTELENCE<span class="Bold"><span class="Sup">®</span></span> is a human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in treatment-experienced patients 6 years of age and older with viral <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> resistant to an NNRTI and other antiretroviral agents. (<a href="#S1">1</a>) </p>
<p class="Highlighta">In patients who have experienced virologic failure on an NNRTI-containing regimen, do not use INTELENCE<span class="Bold"><span class="Sup">®</span></span> in combination with only N[t]RTIs. (<a href="#S1">1</a>) </p>
<p class="Highlighta">Treatment history and resistance testing should guide the use of INTELENCE<span class="Sup">®</span>. (<a href="#S1">1</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li> Adult patients: 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal. (<a href="#S2.1">2.1</a>, <a href="#S2.3">2.3</a>)</li>
<li> Pediatric patients (6 years to less than 18 years of age and weighing at least 16 kg): dosage of INTELENCE<span class="Sup">®</span> is based on body weight and should not exceed the recommended adult dose. (<a href="#S2.2">2.2</a>, <a href="#S2.3">2.3</a>)</li>
<li> INTELENCE<span class="Bold"><span class="Sup">®</span></span> tablets should be taken following a meal. (<a href="#S2.2">2.2</a>, <a href="#S2.3">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">25 mg tablets, 100 mg tablets and 200 mg tablets (<a href="#S3">3</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><p class="Highlighta">Severe, potentially life threatening and fatal <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been reported. This includes cases of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. Immediately discontinue treatment if severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with systemic symptoms or liver transaminase elevations develops and monitor clinical status, including liver transaminases closely. (<a href="#S5.1">5.1</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse drug reactions of moderate to severe intensity (at least 2%) which occurred at a higher rate than placebo in adults are <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. (<a href="#S6.1">6.1</a>) </p>
<p class="Highlighta">The most common adverse drug reactions in at least 2% of pediatric patients are <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (<a href="#S6.2">6.2</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Janssen Products, LP at 1-800-JANSSEN </span><span class="Bold">(1-800-526-7736) or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">INTELENCE<span class="Bold"><span class="Sup">®</span></span> should not be co-administered with the following antiretrovirals: </p>
<ul>
<li> Tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir</li>
<li> Protease inhibitors administered without ritonavir</li>
<li> NNRTIs</li>
</ul>
<p class="Highlighta">Co-administration of INTELENCE<span class="Bold"><span class="Sup">®</span></span> with drugs that inhibit or induce CYP3A, CYP2C9, and/or CYP2C19 may alter the therapeutic effect or adverse reaction profile of etravirine. (<a href="#S7">7</a>) </p>
<p class="Highlighta">Co-administration of INTELENCE<span class="Bold"><span class="Sup">®</span></span> with drugs that are substrates of CYP3A, CYP2C9, and/or CYP2C19 or are transported by P-glycoprotein may alter the therapeutic effect or adverse reaction profile of the co-administered drug(s). (<a href="#S7">7</a>) </p>
<p class="Highlighta">  Refer to the Full Prescribing Information for other drugs that should not be co-administered with INTELENCE<span class="Bold"><span class="Sup">®</span></span> and for other drugs that may require a change in dose or regimen. (<a href="#S7">7</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Nursing Mothers: Mothers should not breastfeed due to the potential for HIV transmission. (<a href="#S8.3">8.3</a>)</li></ul></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 1/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Adult Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2          Pediatric Patients (6 years to less than 18 years of age)</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Method of Administration</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h2><a href="#section-3.1" class="toc">3.1 INTELENCE<span class="Sup">®</span> 25 mg Tablets</a></h2>
<h2><a href="#section-3.2" class="toc">3.2          INTELENCE<span class="Sup">®</span> 100 mg Tablets</a></h2>
<h2><a href="#section-3.3" class="toc">3.3          INTELENCE<span class="Sup">®</span> 200 mg Tablets</a></h2>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5              WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1          Severe Skin and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2          Fat Redistribution</a></h2>
<h2><a href="#section-5.3" class="toc">5.3          <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1          Clinical Trials Experience: Adults</a></h2>
<h2><a href="#section-6.2" class="toc">6.2          Clinical Trials Experience: Pediatric Subjects (6 years to less than 18 years of age)</a></h2>
<h2><a href="#section-6.3" class="toc">6.3          Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8              USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6          <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7          <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4	Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Treatment-Experienced Adult Subjects</a></h2>
<h2><a href="#section-13.2" class="toc">14.2        Treatment-Experienced Pediatric Subjects (6 years to less than 18 years of age)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17           PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">INTELENCE<span class="Sup">®</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a>, in combination with other antiretroviral agents, is indicated for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus type 1 (HIV-1) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in antiretroviral treatment-experienced patients ages 6 years and older, who have evidence of viral replication and HIV-1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The indication for adult use is based on Week 48 analyses from 2 randomized, double-blind, placebo-controlled trials of INTELENCE<span class="Sup">®</span>. Both studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults. The indication for pediatric use is based on 24-week analyses of a single-arm, Phase 2 trial in antiretroviral treatment-experienced pediatric subjects 6 years to less than 18 years of age [<span class="Italics">see <a href="#S8.4">Use in Specific Populations (8.4)</a></span>].</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with INTELENCE<span class="Sup">®</span>:</span></p>
<ul>
<li style="border-left:1px solid;"><span class="XmChange">Treatment history and resistance testing should guide the use of INTELENCE<span class="Sup">®</span> due to concerns for potential cross-resistance [<span class="Italics">see <a href="#S12.4">Microbiology (12.4)</a> and <a href="#S14">Clinical Studies (14)</a></span>].</span></li>
<li style="border-left:1px solid;"><span class="XmChange">In patients who have experienced virologic failure on an NNRTI-containing regimen, do not use INTELENCE<span class="Sup">®</span> in combination with only N[t]RTIs [<span class="Italics">see <a href="#S14">Clinical Studies (14)</a></span>].</span></li>
<li style="border-left:1px solid;"><span class="XmChange">The use of other active antiretroviral agents with INTELENCE<span class="Sup">®</span> is associated with an increased likelihood of treatment response.</span></li>
<li style="border-left:1px solid;"><span class="XmChange">The safety and efficacy of INTELENCE<span class="Sup">®</span> have not been established in pediatric patients less than 6 years of age or in treatment-naïve adult or pediatric patients.</span></li>
</ul>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>Registered trademark of Tibotec Pharmaceuticals</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Adult Patients</h2>
<p class="First">The recommended oral dose of INTELENCE<span class="Sup">®</span> tablets is 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. The type of food does not affect the exposure to etravirine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2          Pediatric Patients (6 years to less than 18 years of age)</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended dose of INTELENCE<span class="Sup">®</span> for pediatric patients 6 years to less than 18 years of age and weighing at least 16 kg is based on body weight (see <a href="#tb">table below</a>) not exceeding the recommended adult dose. INTELENCE tablet(s) should be taken orally, following a meal [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. The type of food does not affect the exposure to etravirine.</span></p>
<a name="tb"></a><table width="90%">
<caption><span>Recommended dose of INTELENCE<span class="Sup">®</span> for pediatric patients 6 years to less than 18 years of age</span></caption>
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center"><span class="XmChange">Weight<br> kilograms (kg)</span></th>
<th class="Rrule" align="center">Dose</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="XmChange">greater than or equal to 16 kg to less than 20 kg</span></td>
<td class="Rrule" align="center">100 mg twice daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="XmChange">greater than or equal to 20 kg to less than 25 kg</span></td>
<td class="Rrule" align="center">125 mg twice daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="XmChange">greater than or equal to 25 kg to less than 30 kg</span></td>
<td class="Rrule" align="center">150 mg twice daily</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="XmChange">greater than or equal to 30 kg</span></td>
<td class="Rrule" align="center">200 mg twice daily</td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;"><span class="XmChange">The safety and efficacy of INTELENCE<span class="Sup">®</span> have not been established in children less than 6 years of age [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Healthcare professionals should pay special attention to the accurate dose selection of INTELENCE<span class="Sup">®</span>, the transcription of the medication order, the dispensing information and the dosing instructions to minimize the risk of medication errors, overdosing, and underdosing.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Method of Administration</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Patients should be instructed to swallow the INTELENCE<span class="Sup">®</span> tablet(s) whole with a liquid such as water. Patients who are unable to swallow the INTELENCE<span class="Sup">®</span> tablet(s) whole may disperse the tablet(s) in a glass of water. The patient should be instructed to do the following:</span></p>
<ul class="Circle">
<li style="border-left:1px solid;"><span class="XmChange">place the tablet(s) in 5 ml (1 teaspoon) of water, or at least enough liquid to cover the medication,</span></li>
<li style="border-left:1px solid;"><span class="XmChange">stir well until the water looks milky,</span></li>
<li style="border-left:1px solid;"><span class="XmChange">if desired, add more water or alternatively orange juice or milk (patients should not place the tablets in orange juice or milk without first adding water). The use of grapefruit juice or warm (greater than 40°C) or carbonated beverages should be avoided.</span></li>
<li style="border-left:1px solid;"><span class="XmChange">drink it immediately,</span></li>
<li style="border-left:1px solid;"><span class="XmChange">rinse the glass several times with water, orange juice, or milk and completely swallow the rinse each time to make sure the patient takes the entire dose.</span></li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S3.1"></a><a name="section-3.1"></a><p></p>
<h2>3.1 INTELENCE<span class="Sup">®</span> 25 mg Tablets</h2>
<p class="First">INTELENCE<span class="Sup">®</span> 25 mg tablets are supplied as white to off-white, oval, scored tablets debossed with "TMC" on one side.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S3.2"></a><a name="section-3.2"></a><p></p>
<h2>3.2          INTELENCE<span class="Sup">®</span> 100 mg Tablets</h2>
<p class="First">INTELENCE<span class="Sup">®</span> 100 mg tablets are supplied as white to off-white oval tablets debossed with "TMC125" on one side and "100" on the other side.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S3.3"></a><a name="section-3.3"></a><p></p>
<h2>3.3          INTELENCE<span class="Sup">®</span> 200 mg Tablets</h2>
<p class="First">INTELENCE<span class="Sup">®</span> 200 mg tablets are supplied as white to off-white, biconvex, oblong tablets debossed with "T200" on one side.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5              WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1          Severe Skin and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Severe, potentially life-threatening, and fatal <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been reported. These include cases of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have also been reported and were characterized by <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, constitutional findings, and sometimes organ dysfunction, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>. In Phase 3 clinical trials, Grade 3 and 4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> were reported in 1.3% of subjects receiving INTELENCE<span class="Sup">®</span> compared to 0.2% of placebo subjects. A total of 2.2% of HIV-1-infected subjects receiving INTELENCE<span class="Sup">®</span> discontinued from Phase 3 trials due to <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> [<span class="Italics">see <a href="#S6">Adverse Reactions (6)</a></span>]. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> occurred most commonly during the first 6 weeks of therapy.</p>
<p>Discontinue INTELENCE<span class="Sup">®</span> immediately if signs or symptoms of severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> develop (including, but not limited to, severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="43530620" conceptname="Oral lesion">oral lesions</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>). Clinical status including liver transaminases should be monitored and appropriate therapy initiated. Delay in stopping INTELENCE<span class="Sup">®</span> treatment after the onset of severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may result in a life-threatening reaction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2          Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body fat, including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and "<span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3          <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including INTELENCE<span class="Sup">®</span>. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jiroveci</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP) or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Graves' disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described in greater detail in other sections:</p>
<ul class="Disc"><li>Severe skin and   <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</li></ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1          Clinical Trials Experience: Adults</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The safety assessment is based on all data from 1203 subjects in the Phase 3 placebo-controlled trials, TMC125-C206 and TMC125-C216, conducted in antiretroviral treatment-experienced HIV-1-infected adult subjects, 599 of whom received INTELENCE<span class="Sup">®</span> (200 mg twice daily). In these pooled trials, the median exposure for subjects in the INTELENCE<span class="Sup">®</span> arm and placebo arm was 52.3 and 51.0 weeks, respectively. Discontinuations due to adverse drug reactions (ADRs) were 5.2% in the INTELENCE<span class="Sup">®</span> arm and 2.6% in the placebo arm.</p>
<p>The most frequently reported ADR at least Grade 2 in severity was <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (10.0%). <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> reaction and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> were reported in less than 0.1% of subjects during clinical development with INTELENCE<span class="Sup">®</span> [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>]. A total of 2.2% of HIV-1-infected subjects in Phase 3 trials receiving INTELENCE<span class="Sup">®</span> discontinued due to <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In general, in clinical trials, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was mild to moderate, occurred primarily in the second week of therapy, and was infrequent after Week 4. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> generally resolved within 1 to 2 weeks on continued therapy. The incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was higher in women compared to men in the INTELENCE<span class="Sup">®</span> arm in the Phase 3 trials. Patients with a history of NNRTI-related <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> did not appear to be at increased risk for the development of INTELENCE<span class="Sup">®</span>-related <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> compared to patients without a history of NNRTI-related <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics">Common Adverse Reactions</span></p>
<p>Clinical ADRs of moderate intensity or greater (greater than or equal to Grade 2) and reported in at least 2% of subjects treated with INTELENCE<span class="Sup">®</span> and occurring at a higher rate compared to placebo (excess of 1%) are presented in Table 1. Laboratory abnormalities considered ADRs are included in Table 2.</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1: Treatment-Emergent Adverse Reactions<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> of at least Moderate Intensity<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a> (Grades 2 to 4) in at least 2% of Adult Subjects in the INTELENCE<span class="Sup">®</span> Treatment Groups and at a higher rate compared to placebo (excess of 1%)</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2">System Organ Class, <br>Preferred Term,<br> %</th>
<th class="Botrule Rrule" align="center" colspan="2">Pooled TMC125-C206 and TMC125-C216 Trials</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">INTELENCE<span class="Sup">®</span> + BR<br>N=599</th>
<th class="Rrule" align="center">Placebo + BR<br>N=604</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">N=total number of subjects per treatment group, BR=background regimen</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Includes adverse reactions at least possibly, probably, or very likely related to the drug.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>Intensities are defined as follows: Moderate (<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> enough to cause interference with usual activity); Severe (incapacitating with inability to work or do usual activity).</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">  <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Rrule" align="center" colspan="2"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span></td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">  Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Rrule" align="center" colspan="2"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="center">10%</td>
<td class="Rrule" align="center">3%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics">Less Common Adverse Reactions</span></p>
<p>Treatment-emergent ADRs occurring in less than 2% of subjects (599 subjects) receiving INTELENCE<span class="Sup">®</span> and of at least moderate intensity (greater than or equal to Grade 2) are listed below by body system:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span></p>
<p><span class="Italics">Ear and Labyrinth Disorders</span>: <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="4309379" conceptname="Retching">retching</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span></p>
<p><span class="Italics">General Disorders and Administration Site Conditions</span>: <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">sluggishness</span></p>
<p><span class="Italics">Hematologic Disorders</span>: <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span></p>
<p><span class="Italics">Hepatobiliary Disorders</span>: <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">cytolytic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span></p>
<p><span class="Italics">Metabolism and Nutrition Disorders</span>: <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p><span class="Italics">Psychiatric Disorders</span>: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span></p>
<p><span class="Italics">Renal and Urinary Disorders: </span><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span></p>
<p><span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span></p>
<p><span class="Italics">Respiratory,Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4263848" conceptname="Dyspnea on exertion">exertional dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders</span>: <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span>, <span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">lipohypertrophy</span>, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">prurigo</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling face</span></p>
<p>Additional ADRs of at least moderate intensity observed in other trials were acquired <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> and <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">haemorrhagic stroke</span>, each reported in no more than 0.5% of subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Italics">Laboratory Abnormalities in Treatment-Experienced Patients</span></p>
<p>Selected Grade 2 to Grade 4 laboratory abnormalities that represent a worsening from baseline observed in adult subjects treated with INTELENCE<span class="Sup">®</span> are presented in Table 2.</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2: Selected Grade 2 to 4 Laboratory Abnormalities Observed in Treatment-Experienced Subjects</span></caption>
<col align="left" valign="middle" width="28%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="24%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center" colspan="2">Pooled TMC125-C206 and TMC125-C216 Trials</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left">Laboratory Parameter<br>                                       Preferred Term,<br> %</th>
<th class="Rrule" align="center" valign="top">DAIDS Toxicity Range</th>
<th class="Rrule" align="center">INTELENCE<span class="Sup">®</span> + BR<br>N=599</th>
<th class="Rrule" align="center">Placebo + BR<br>N=604</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="4">ULN=Upper Limit of Normal, BR=background regimen</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">GENERAL BIOCHEMISTRY</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Pancreatic amylase</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Grade 2</td>
<td class="Rrule Toprule" align="center">&gt; 1.5–2 × ULN</td>
<td class="Rrule Toprule" align="center">7%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="center">&gt; 2–5 × ULN</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 4</td>
<td class="Rrule" align="center">&gt; 5 × ULN</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Lipase</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Grade 2</td>
<td class="Rrule Toprule" align="center">&gt; 1.5–3 × ULN</td>
<td class="Rrule Toprule" align="center">4%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="center">&gt; 3–5 × ULN</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 4</td>
<td class="Rrule" align="center">&gt; 5×ULN</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Creatinine</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 2</td>
<td class="Rrule" align="center">&gt; 1.4–1.8 × ULN</td>
<td class="Rrule" align="center">6%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="center">&gt; 1.9–3.4 × ULN</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 4</td>
<td class="Rrule" align="center">&gt; 3.4 × ULN</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">HEMATOLOGY</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Decreased hemoglobin</span></span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Grade 2</td>
<td class="Rrule Toprule" align="center">90–99 g/L</td>
<td class="Rrule Toprule" align="center">2%</td>
<td class="Botrule Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Grade 3</td>
<td class="Rrule Toprule" align="center">70–89 g/L</td>
<td class="Rrule Toprule" align="center">&lt; 1%</td>
<td class="Botrule Rrule" align="center">&lt; 1%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Grade 4</td>
<td class="Rrule Toprule" align="center">&lt; 70 g/L</td>
<td class="Rrule Toprule" align="center">&lt; 1%</td>
<td class="Botrule Rrule" align="center">&lt; 1%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">White blood cell count</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Grade 2</td>
<td class="Rrule Toprule" align="center">1,500–1,999/mm<span class="Sup">3</span>
</td>
<td class="Rrule Toprule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="center">1,000–1,499/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 4</td>
<td class="Rrule" align="center">&lt; 1,000/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Grade 2</td>
<td class="Rrule Toprule" align="center">750–999/mm<span class="Sup">3</span>
</td>
<td class="Rrule Toprule" align="center">5%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="center">500–749/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 4</td>
<td class="Rrule" align="center">&lt; 500/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Platelet count</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Grade 2</td>
<td class="Rrule Toprule" align="center">50,000–99,999/mm<span class="Sup">3</span>
</td>
<td class="Rrule Toprule" align="center">3%</td>
<td class="Botrule Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Grade 3</td>
<td class="Rrule Toprule" align="center">25,000–49,999/mm<span class="Sup">3</span>
</td>
<td class="Rrule Toprule" align="center">1%</td>
<td class="Botrule Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Grade 4</td>
<td class="Rrule Toprule" align="center">&lt; 25,000/mm<span class="Sup">3</span>
</td>
<td class="Rrule Toprule" align="center">&lt; 1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">LIPIDS AND GLUCOSE</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 2</td>
<td class="Rrule" align="center">&gt; 6.20–7.77 mmol/L<br> 240–300 mg/dL</td>
<td class="Rrule" align="center">20%</td>
<td class="Rrule" align="center">17%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="center">&gt; 7.77 mmol/L<br> &gt; 300 mg/dL</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Low density lipoprotein</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 2</td>
<td class="Rrule" align="center">4.13–4.9 mmol/L<br> 160–190 mg/dL</td>
<td class="Rrule" align="center">13%</td>
<td class="Rrule" align="center">12%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="center">&gt; 4.9 mmol/L<br> &gt; 190 mg/dL</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Triglycerides</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 2</td>
<td class="Rrule" align="center">5.65–8.48 mmol/L<br> 500 –750 mg/dL</td>
<td class="Rrule" align="center">9%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="center">8.49–13.56 mmol/L<br> 751 – 1200 mg/dL</td>
<td class="Rrule" align="center">6%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 4</td>
<td class="Rrule" align="center">&gt; 13.56 mmol/L<br> &gt; 1200 mg/dL</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Elevated glucose levels</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Grade 2</td>
<td class="Rrule Toprule" align="center">6.95–13.88 mmol/L<br> 161–250 mg/dL</td>
<td class="Rrule Toprule" align="center">15%</td>
<td class="Rrule" align="center">13%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="center">13.89–27.75 mmol/L<br> 251 – 500 mg/dL</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 4</td>
<td class="Rrule" align="center">&gt; 27.75 mmol/L<br> &gt; 500 mg/dL</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">HEPATIC PARAMETERS</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Alanine amino transferase</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Grade 2</td>
<td class="Rrule Toprule" align="center">2.6–5 × ULN</td>
<td class="Rrule Toprule" align="center">6%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="center">5.1–10 × ULN</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 4</td>
<td class="Rrule" align="center">&gt; 10 × ULN</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Aspartate amino transferase</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left">Grade 2</td>
<td class="Rrule Toprule" align="center">2.6–5 × ULN</td>
<td class="Rrule Toprule" align="center">6%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Grade 3</td>
<td class="Rrule" align="center">5.1–10 × ULN</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Grade 4</td>
<td class="Rrule" align="center">&gt; 10 × ULN</td>
<td class="Rrule" align="center">&lt; 1%</td>
<td class="Rrule" align="center">&lt; 1%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Italics">Patients co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus</span></p>
<p>In Phase 3 trials TMC125-C206 and TMC125-C216, 139 subjects (12.3%) with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B and/or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> out of 1129 subjects were permitted to enroll. AST and ALT abnormalities occurred more frequently in <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus co-infected subjects for both treatment groups. Grade 2 or higher laboratory abnormalities that represent a worsening from baseline of AST, ALT or total bilirubin occurred in 27.8%, 25.0% and 7.1% respectively, of INTELENCE<span class="Sup">®</span>-treated co-infected subjects as compared to 6.7%, 7.5% and 1.8% of non-co-infected INTELENCE<span class="Sup">®</span>-treated subjects. In general, adverse events reported by INTELENCE<span class="Sup">®</span>-treated subjects with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> were similar to INTELENCE<span class="Sup">®</span>-treated subjects without <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2          Clinical Trials Experience: Pediatric Subjects (6 years to less than 18 years of age)</h2>
<p class="First">The safety assessment in children and adolescents is based on the Week 24 analysis of the single-arm, Phase 2 trial TMC125-C213 in which 101 antiretroviral treatment-experienced HIV-1 infected subjects 6 years to less than 18 years of age and weighing at least 16 kg received INTELENCE in combination with other antiretroviral agents [<span class="Italics">see </span><span class="Italics"><a href="#S14.2">Clinical Studies (14.2)</a></span>]. The frequency, type and severity of adverse drug reactions in pediatric subjects were comparable to those observed in adult subjects, except for <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> which was observed more frequently in pediatric subjects. The most common adverse drug reactions in at least 2% of pediatric subjects were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (greater than or equal to Grade 2) occurred in 15% of pediatric subjects. In the majority of cases, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was mild to moderate, of macular/papular type, and occurred in the second week of therapy. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> was self-limiting and generally resolved within 1 week on continued therapy. The discontinuation rate for <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was 4%. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> including serious (Grade 3 or 4) events and discontinuations were more frequently observed in female subjects compared to male subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3          Postmarketing Experience</h2>
<p class="First">The following events have been identified during postmarketing use of INTELENCE<span class="Sup">®</span>. Because these events are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span>: Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have been reported [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders</span>: Fatal cases of <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Etravirine is a substrate of CYP3A, CYP2C9, and CYP2C19. Therefore, co-administration of INTELENCE<span class="Sup">®</span> with drugs that induce or inhibit CYP3A, CYP2C9, and CYP2C19 may alter the therapeutic effect or adverse reaction profile of INTELENCE<span class="Sup">®</span> (see <a href="#table3">Table 3</a>). [<span class="Italics">See also <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>.]</p>
<p>Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein. Therefore, co-administration of drugs that are substrates of CYP3A, CYP2C9 and CYP2C19 or are transported by P-glycoprotein with INTELENCE<span class="Sup">®</span> may alter the therapeutic effect or adverse reaction profile of the co-administered drug(s) (see <a href="#table3">Table 3</a>).<span class="Italics"> [See also <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>.]</p>
<p>Table 3 shows the established and other potentially significant drug interactions based on which, alterations in dose or regimen of INTELENCE<span class="Sup">®</span> and/or co-administered drug may be recommended. Drugs that are not recommended for co-administration with INTELENCE<span class="Sup">®</span> are also included in Table 3.</p>
<a name="table3"></a><table width="100%">
<caption><span>Table 3: Established and Other Potentially Significant Drug Interactions: Alterations in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction [See <a href="#S12.3">Clinical Pharmacology (12.3)</a>] </span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="55%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Concomitant Drug Class:<br>Drug Name</th>
<th class="Rrule" align="left">Effect on Concentration of Etravirine or Concomitant Drug</th>
<th class="Rrule" align="left">Clinical Comment</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">↑ = increase, ↓ = decrease, ↔ = no change</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>The interaction between INTELENCE<span class="Sup">®</span> and the drug was evaluated in a clinical study. All other drug interactions shown are predicted.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">HIV-Antiviral Agents: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">efavirenz<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a><br> nevirapine<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↓ etravirine</td>
<td class="Rrule" align="left">Combining two NNRTIs has not been shown to be beneficial. Concomitant use of INTELENCE<span class="Sup">®</span> with efavirenz or nevirapine may cause a significant decrease in the plasma concentrations of etravirine and loss of therapeutic effect of INTELENCE<span class="Sup">®</span>. INTELENCE<span class="Sup">®</span> and other NNRTIs should not be co-administered.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">delavirdine</td>
<td class="Rrule" align="left">↑ etravirine</td>
<td class="Rrule" align="left">Combining two NNRTIs has not been shown to be beneficial. INTELENCE<span class="Sup">®</span> and delavirdine should not be co-administered.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">rilpivirine</td>
<td class="Rrule" align="left">↓ rilpivirine<br>↔ etravirine</td>
<td class="Rrule" align="left">Combining two NNRTIs has not been shown to be beneficial. INTELENCE<span class="Sup">®</span> and rilpivirine should not be coadministered.</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">HIV-Antiviral Agents: Protease Inhibitors (PIs)</span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">atazanavir<a href="#footnote-4" class="Sup">*</a><br>(without ritonavir)</td>
<td class="Rrule" align="left">↓ atazanavir</td>
<td class="Rrule" align="left">Concomitant use of INTELENCE<span class="Sup">®</span> with atazanavir without low-dose ritonavir may cause a significant alteration in the plasma concentration of atazanavir. INTELENCE<span class="Sup">®</span> should not be co-administered with atazanavir without low-dose ritonavir.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">atazanavir/ritonavir<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="left">↓ atazanavir<br>↑ etravirine</td>
<td class="Rrule" align="left">Concomitant use of INTELENCE<span class="Sup">®</span> with atazanavir/ritonavir may cause a significant decrease in atazanavir C<span class="Sub">min</span> and loss of therapeutic effect of atazanavir. In addition, the mean systemic exposure (AUC) of etravirine after co-administration of INTELENCE<span class="Sup">®</span> with atazanavir/ritonavir is anticipated to be higher than the mean systemic exposure of etravirine observed in the Phase 3 trials after co-administration of INTELENCE<span class="Sup">®</span> and darunavir/ritonavir (as part of the background regimen). INTELENCE<span class="Sup">®</span> and atazanavir/ritonavir should not be co-administered.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">darunavir/ritonavir<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↓ etravirine</td>
<td class="Rrule" align="left">The mean systemic exposure (AUC) of etravirine was reduced when INTELENCE<span class="Sup">®</span> was co-administered with darunavir/ritonavir. Because all subjects in the Phase 3 trials received darunavir/ritonavir as part of the background regimen and etravirine exposures from these trials were determined to be safe and effective, INTELENCE<span class="Sup">®</span> and darunavir/ritonavir can be co-administered without dose adjustments.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">fosamprenavir<br>(without ritonavir)</td>
<td class="Rrule" align="left">↑ amprenavir</td>
<td class="Rrule" align="left">Concomitant use of INTELENCE<span class="Sup">®</span> with fosamprenavir without low-dose ritonavir may cause a significant alteration in the plasma concentration of amprenavir. INTELENCE<span class="Sup">®</span> should not be co-administered with fosamprenavir without low-dose ritonavir.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">fosamprenavir/ritonavir<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↑ amprenavir</td>
<td class="Rrule" align="left">Due to a significant increase in the systemic exposure of amprenavir, the appropriate doses of the combination of INTELENCE<span class="Sup">®</span> and fosamprenavir/ritonavir have not been established. INTELENCE<span class="Sup">®</span> and fosamprenavir/ritonavir should not be co-administered.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">indinavir<a href="#footnote-4" class="Sup">*</a><br>(without ritonavir)</td>
<td class="Rrule" align="left">↓ indinavir</td>
<td class="Rrule" align="left">Concomitant use of INTELENCE<span class="Sup">®</span> with indinavir without low-dose ritonavir may cause a significant alteration in the plasma concentration of indinavir. INTELENCE<span class="Sup">®</span> should not be co-administered with indinavir without low-dose ritonavir.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">lopinavir/ritonavir<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↓ etravirine</td>
<td class="Rrule" align="left">The mean systemic exposure (AUC) of etravirine was reduced after co-administration of INTELENCE<span class="Sup">®</span> with lopinavir/ritonavir (tablet). Because the reduction in the mean systemic exposures of etravirine in the presence of lopinavir/ritonavir is similar to the reduction in mean systemic exposures of etravirine in the presence of darunavir/ritonavir, INTELENCE<span class="Sup">®</span> and lopinavir/ritonavir can be co-administered without dose adjustments.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">nelfinavir<br>(without ritonavir)</td>
<td class="Rrule" align="left">↑ nelfinavir</td>
<td class="Rrule" align="left">Concomitant use of INTELENCE<span class="Sup">®</span> with nelfinavir without low-dose ritonavir may cause a significant alteration in the plasma concentration of nelfinavir. INTELENCE<span class="Sup">®</span> should not be co-administered with nelfinavir without low-dose ritonavir.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ritonavir<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↓ etravirine</td>
<td class="Rrule" align="left">Concomitant use of INTELENCE<span class="Sup">®</span> with ritonavir 600 mg twice daily may cause a significant decrease in the plasma concentration of etravirine and loss of therapeutic effect of INTELENCE<span class="Sup">®</span>. INTELENCE<span class="Sup">®</span> and ritonavir 600 mg twice daily should not be co-administered.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">saquinavir/ritonavir<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↓ etravirine</td>
<td class="Rrule" align="left">The mean systemic exposure (AUC) of etravirine was reduced when INTELENCE<span class="Sup">®</span> was co-administered with saquinavir/ritonavir. Because the reduction in the mean systemic exposures of etravirine in the presence of saquinavir/ritonavir is similar to the reduction in mean systemic exposures of etravirine in the presence of darunavir/ritonavir, INTELENCE<span class="Sup">®</span> and saquinavir/ritonavir can be co-administered without dose adjustments.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">tipranavir/ritonavir<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↓ etravirine</td>
<td class="Rrule" align="left">Concomitant use of INTELENCE<span class="Sup">®</span> with tipranavir/ritonavir may cause a significant decrease in the plasma concentrations of etravirine and loss of therapeutic effect of INTELENCE<span class="Sup">®</span>. INTELENCE<span class="Sup">®</span> and tipranavir/ritonavir should not be co-administered.</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">CCR5 Antagonists</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">maraviroc<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↔ etravirine<br>↓ maraviroc </td>
<td class="Rrule" align="left">When INTELENCE<span class="Sup">®</span> is co-administered with maraviroc in the absence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 600 mg twice daily. No dose adjustment of INTELENCE<span class="Sup">®</span> is needed.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">maraviroc/darunavir/ritonavir<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↔ etravirine<br>↑ maraviroc</td>
<td class="Rrule" align="left">When INTELENCE<span class="Sup">®</span> is co-administered with maraviroc in the presence of a potent CYP3A inhibitor (e.g., ritonavir boosted protease inhibitor), the recommended dose of maraviroc is 150 mg twice daily. No dose adjustment of INTELENCE<span class="Sup">®</span> is needed.</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Other Agents</span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">
<span class="Bold">Antiarrhythmics</span>:<br>digoxin<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↔ etravirine<br>↑ digoxin</td>
<td class="Rrule" align="left">For patients who are initiating a combination of INTELENCE<span class="Sup">®</span> and digoxin, the lowest dose of digoxin should initially be prescribed. For patients on a stable digoxin regimen and initiating INTELENCE<span class="Sup">®</span>, no dose adjustment of either INTELENCE<span class="Sup">®</span> or digoxin is needed. The serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">										amiodarone,<br> bepridil,<br> disopyramide,<br> flecainide,<br> lidocaine (systemic),<br> mexiletine,<br> propafenone,<br> quinidine</td>
<td class="Rrule" align="left">↓ antiarrhythmics</td>
<td class="Rrule" align="left">Concentrations of these antiarrhythmics may be decreased when co-administered with INTELENCE<span class="Sup">®</span>. INTELENCE<span class="Sup">®</span> and antiarrhythmics should be co-administered with caution. Drug concentration monitoring is recommended, if available.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Anticoagulants</span>:<br> warfarin</td>
<td class="Rrule Toprule" align="left">↑ anticoagulants</td>
<td class="Rrule Toprule" align="left">Warfarin concentrations may be increased when co-administered with INTELENCE<span class="Sup">®</span>. The international normalized ratio (INR) should be monitored when warfarin is combined with INTELENCE<span class="Sup">®</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Anticonvulsants</span>:<br> carbamazepine,<br> phenobarbital,<br> phenytoin</td>
<td class="Rrule Toprule" align="left">↓ etravirine</td>
<td class="Rrule Toprule" align="left">Carbamazepine, phenobarbital and phenytoin are inducers of CYP450 enzymes. INTELENCE<span class="Sup">®</span> should not be used in combination with carbamazepine, phenobarbital, or phenytoin as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of INTELENCE<span class="Sup">®</span>.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">
<span class="Bold">Antifungals</span>:<br>  fluconazole<a href="#footnote-4" class="Sup">*</a>,<br>  voriconazole<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↑ etravirine<br>  ↔ fluconazole<br>  ↑ voriconazole</td>
<td class="Rrule" align="left">Co-administration of etravirine and fluconazole significantly increased etravirine exposures. The amount of safety data at these increased etravirine exposures is limited, therefore, etravirine and fluconazole should be co-administered with caution. No dose adjustment of INTELENCE<span class="Sup">®</span> or fluconazole is needed.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">Co-administration of etravirine and voriconazole significantly increased etravirine exposures. The amount of safety data at these increased etravirine exposures is limited, therefore, etravirine and voriconazole should be co-administered with caution. No dose adjustment of INTELENCE<span class="Sup">®</span> or voriconazole is needed.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Antifungals</span>:<br>itraconazole,<br>ketoconazole,<br>posaconazole</td>
<td class="Rrule" align="left">↑ etravirine<br>↓ itraconazole<br>↓ ketoconazole<br>↔ posaconazole</td>
<td class="Rrule" align="left">Posaconazole, a potent inhibitor of CYP3A4, may increase plasma concentrations of etravirine. Itraconazole and ketoconazole are potent inhibitors as well as substrates of CYP3A4. Concomitant systemic use of itraconazole or ketoconazole and INTELENCE<span class="Sup">®</span> may increase plasma concentrations of etravirine. Simultaneously, plasma concentrations of itraconazole or ketoconazole may be decreased by INTELENCE<span class="Sup">®</span>. Dose adjustments for itraconazole, ketoconazole or posaconazole may be necessary depending on the other co-administered drugs.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Antiinfectives</span>:<br> clarithromycin<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="left">↑ etravirine<br> ↓ clarithromycin<br> ↑ 14-OH-clarithromycin</td>
<td class="Rrule" align="left">Clarithromycin exposure was decreased by INTELENCE<span class="Sup">®</span>; however, concentrations of the active metabolite, 14-hydroxy-clarithromycin, were increased. Because 14-hydroxy-clarithromycin has reduced activity against <span class="Italics">Mycobacterium avium</span> complex (MAC), overall activity against this pathogen may be altered. Alternatives to clarithromycin, such as azithromycin, should be considered for the treatment of MAC.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Antimycobacterials:</span><br> rifampin,<br> rifapentine</td>
<td class="Rrule" align="left">↓ etravirine</td>
<td class="Rrule" align="left">Rifampin and rifapentine are potent inducers of CYP450 enzymes. INTELENCE<span class="Sup">®</span> should not be used with rifampin or rifapentine as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of INTELENCE<span class="Sup">®</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Antimycobacterials:</span><br> rifabutin<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Lrule Rrule" align="left">↓ etravirine<br> ↓ rifabutin<br> ↓ 25-<span class="Italics">O</span>-desacetylrifabutin</td>
<td class="Rrule" align="left">If INTELENCE<span class="Sup">®</span> is NOT co-administered with a protease inhibitor/ritonavir, then rifabutin at a dose of 300 mg once daily is recommended.<br>If INTELENCE<span class="Sup">®</span> is co-administered with darunavir/ritonavir, lopinavir/ritonavir or saquinavir/ritonavir, then rifabutin should not be co-administered due to the potential for significant reductions in etravirine exposure.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Benzodiazepines:</span><br> diazepam</td>
<td class="Rrule" align="left">↑ diazepam</td>
<td class="Rrule" align="left">Concomitant use of INTELENCE<span class="Sup">®</span> with diazepam may increase plasma concentrations of diazepam. A decrease in diazepam dose may be needed.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Corticosteroids</span>:<br> dexamethasone (systemic)</td>
<td class="Rrule" align="left">↓ etravirine</td>
<td class="Rrule" align="left">Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. This may result in loss of therapeutic effect of INTELENCE<span class="Sup">®</span>. Systemic dexamethasone should be used with caution or alternatives should be considered, particularly for long-term use.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Herbal Products</span>:<br> St. John's wort (<span class="Italics">Hypericum perforatum</span>)</td>
<td class="Rrule" align="left">↓ etravirine</td>
<td class="Rrule" align="left">Concomitant use of INTELENCE<span class="Sup">®</span> with products containing St. John's wort may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of INTELENCE<span class="Sup">®</span>. INTELENCE<span class="Sup">®</span> and products containing St. John's wort should not be co-administered.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">HMG-CoA</span><br><span class="Bold">Reductase Inhibitors</span>:<br> atorvastatin<a href="#footnote-4" class="Sup">*</a><br><br> fluvastatin,<br> lovastatin,<br> pitavastatin,<br>pravastatin,<br> rosuvastatin,<br> simvastatin</td>
<td class="Rrule" align="left">↔ etravirine<br> ↓ atorvastatin<br> ↑ 2-OH-atorvastatin<br><br> ↔ etravirine<br> ↑ fluvastatin,<br> ↓ lovastatin,<br>↑ pitavastatin,<br> ↔ pravastatin,<br> ↔ rosuvastatin,<br> ↓ simvastatin</td>
<td class="Rrule" align="left">The combination of INTELENCE<span class="Sup">®</span> and atorvastatin can be given without dose adjustments, however, the dose of atorvastatin may need to be altered based on clinical response.<br><br> No interaction between pravastatin, rosuvastatin and INTELENCE<span class="Sup">®</span> is expected.<br><br> Lovastatin and simvastatin are CYP3A substrates and co-administration with INTELENCE<span class="Sup">®</span> may result in lower plasma concentrations of the HMG-CoA reductase inhibitor. Fluvastatin and pitavastatin are metabolized by CYP2C9 and co-administration with INTELENCE<span class="Sup">®</span> may result in higher plasma concentrations of the HMG-CoA reductase inhibitor. Dose adjustments for these HMG-CoA reductase inhibitors may be necessary.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Immunosuppressants</span>:<br> cyclosporine,<br> sirolimus,<br> tacrolimus</td>
<td class="Rrule" align="left">↓ immunosuppressant</td>
<td class="Rrule" align="left">INTELENCE<span class="Sup">®</span> and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Narcotic Analgesics/Treatment of Opioid <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></span>:<br> buprenorphine, buprenorphine/naloxone<a href="#footnote-4" class="Sup">*</a>, <br>methadone<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="left">↔ etravirine<br>↓ buprenorphine <br>↔ norbuprenorphine<br>↔ methadone</td>
<td class="Rrule" align="left">INTELENCE<span class="Sup">®</span> and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone) maintenance therapy may need to be adjusted in some patients.<br><br> INTELENCE<span class="Sup">®</span> and methadone can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as methadone maintenance therapy may need to be adjusted in some patients.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Phosphodiesterase Type 5</span><br><span class="Bold">(PDE-5) Inhibitors</span>:<br> sildenafil<a href="#footnote-4" class="Sup">*</a>,<br> tadalafil, <br>vardenafil</td>
<td class="Rrule" align="left">↓ sildenafil<br> ↓ N-desmethyl-sildenafil</td>
<td class="Rrule" align="left">INTELENCE<span class="Sup">®</span> and sildenafil can be co-administered without dose adjustments, however, the dose of sildenafil may need to be altered based on clinical effect.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">
<span class="Bold">Platelet Aggregation Inhibitors:</span><br>clopidogrel</td>
<td class="Rrule" align="left">↓ clopidogrel (active) metabolite</td>
<td class="Rrule" align="left">Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with INTELENCE<span class="Sup">®</span>. Alternatives to clopidogrel should be considered.</td>
</tr>
</tbody>
</table>
<p>In addition to the drugs included in Table 3, the interaction between INTELENCE<span class="Sup">®</span> and the following drugs were evaluated in clinical studies and no dose adjustment is needed for either drug [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]: didanosine, enfuvirtide (ENF), ethinylestradiol/norethindrone, omeprazole, paroxetine, raltegravir, ranitidine, and tenofovir disoproxil fumarate.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8              USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Category B</span></p>
<p>No adequate and well-controlled studies of INTELENCE<span class="Sup">®</span> use in pregnant women have been conducted. In addition, no pharmacokinetic studies have been conducted in pregnant patients. INTELENCE<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Italics">Antiretroviral Pregnancy Registry</span></p>
<p>To monitor maternal-fetal outcomes of pregnant women exposed to INTELENCE<span class="Sup">®</span>, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.3"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>Reproductive and developmental toxicity studies were performed in rabbits (at oral doses up to 375 mg per kg per day) and rats (at oral doses up to 1000 mg per kg per day). In both species, no treatment-related embryo-fetal effects including malformations were observed. In addition, no treatment-related effects were observed in a separate pre- and postnatal study performed in rats at oral doses up to 500 mg per kg per day. The systemic drug exposures achieved in these animal studies were equivalent to those at the recommended human dose (400 mg per day).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing mothers</h2>
<p class="First"><span class="Bold">The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV.</span> It is not known whether etravirine is secreted in human milk. Because of both the potential for HIV transmission and the potential for adverse reactions in nursing infants, <span class="Bold">mothers should be instructed not to breastfeed if they are receiving INTELENCE<span class="Sup">®</span></span>.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric use</h2>
<p class="First">Treatment with INTELENCE<span class="Sup">®</span> is not recommended in children less than 6 years of age. The pharmacokinetics, safety, tolerability and efficacy of INTELENCE<span class="Sup">®</span> in children less than 6 years of age have not been established [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
<p>The safety, pharmacokinetic profile, and virologic and immunologic responses of INTELENCE<span class="Sup">®</span> were evaluated in treatment-experienced HIV-1-infected pediatric subjects 6 years to less than 18 years of age and weighing at least 16 kg [<span class="Italics">see <a href="#S6.2">Adverse Reactions (6.2)</a></span>, <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a> and <a href="#S14.2">Clinical Studies (14.2)</a></span>]. Frequency, type, and severity of adverse drug reactions in pediatric subjects were comparable to those observed in adults, except for <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> [<span class="Italics">see <a href="#S6.2">Adverse Reactions (6.2)</a></span>]. Please see <span class="Italics"><a href="#S2.2">Dosage and Administration (2.2)</a></span> for dosing recommendations for pediatric subjects 6 years to less than 18 years of age and weighing at least 16 kg.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric use</h2>
<p class="First">Clinical studies of INTELENCE<span class="Sup">®</span> did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6          <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dose adjustment of INTELENCE<span class="Sup">®</span> is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The pharmacokinetics of INTELENCE<span class="Sup">®</span> have not been evaluated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>8.7          <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Since the renal clearance of etravirine is negligible (less than 1.2%), a decrease in total body clearance is not expected in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. No dose adjustments are required in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. As etravirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by hemodialysis or peritoneal dialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with INTELENCE<span class="Sup">®</span>. Human experience of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with INTELENCE<span class="Sup">®</span> is limited. The highest dose studied in healthy volunteers was 400 mg once daily. Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with INTELENCE<span class="Sup">®</span> consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. If indicated, elimination of unabsorbed active substance is to be achieved by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage. Administration of activated charcoal may also be used to aid in removal of unabsorbed active substance. Because etravirine is highly protein bound, dialysis is unlikely to result in significant removal of the active substance.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">INTELENCE<span class="Sup">®</span> (etravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus type 1 (HIV-1).</p>
<p>The chemical name for etravirine is 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile. Its molecular formula is C<span class="Sub">20</span>H<span class="Sub">15</span>BrN<span class="Sub">6</span>O and its molecular weight is 435.28. Etravirine has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73667241-b95a-49b0-9c51-a4289f20d5c2&amp;name=intelence-01.jpg"></div>
<p>Etravirine is a white to slightly yellowish brown powder. Etravirine is practically insoluble in water over a wide pH range. It is very slightly soluble in propylene glycol and slightly soluble in ethanol. Etravirine is soluble in polyethylene glycol (PEG)400 and freely soluble in some organic solvents (e.g., N,N-dimethylformamide and tetrahydrofuran).</p>
<p>INTELENCE<span class="Sup">®</span> 25 mg tablets are available as white to off-white, oval scored tablets for oral administration. Each 25 mg tablet contains 25 mg of etravirine and the inactive ingredients hypromellose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate and lactose monohydrate.</p>
<p>INTELENCE<span class="Sup">®</span> 100 mg tablets are available as white to off-white, oval tablets for oral administration. Each 100 mg tablet contains 100 mg of etravirine and the inactive ingredients hypromellose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate and lactose monohydrate.</p>
<p>INTELENCE<span class="Sup">®</span> 200 mg tablets are available as white to off-white, biconvex, oblong tablets for oral administration. Each 200 mg tablet contains 200 mg of etravirine and the inactive ingredients hypromellose, silicified microcrystalline cellulose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Etravirine is an antiviral drug [<span class="Italics">see <a href="#S12.4">Microbiology (12.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Effects on Electrocardiogram</span></p>
<p>In a randomized, double-blind, active, and placebo-controlled crossover study, 41 healthy subjects were administered INTELENCE<span class="Sup">®</span> 200 mg twice daily, INTELENCE<span class="Sup">®</span> 400 mg once daily, placebo, and moxifloxacin 400 mg. After 8 days of dosing, etravirine did not prolong the QT interval. The maximum mean (upper 1-sided 95% CI) baseline and placebo-adjusted QTcF were 0.6 ms (3.3 ms) for 200 mg twice daily and -1.0 ms (2.5 ms) for 400 mg once daily dosing regimens.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics">Pharmacokinetics in Adults</span></p>
<p>The pharmacokinetic properties of INTELENCE<span class="Sup">®</span> were determined in healthy adult subjects and in treatment-experienced HIV-1-infected adult and pediatric subjects. The systemic exposures (AUC) to etravirine were lower in HIV-1-infected subjects than in healthy subjects.</p>
<a name="table4"></a><table width="100%">
<caption><span>Table 4: Population Pharmacokinetic Estimates of Etravirine 200 mg twice daily in HIV-1-Infected Adult Subjects (Integrated Data from Phase 3 Trials at Week 48)<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Parameter</th>
<th class="Rrule" align="center">Etravirine 200 mg twice daily<br>N = 575</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>All HIV-1-infected subjects enrolled in Phase 3 clinical trials received darunavir/ritonavir 600/100 mg twice daily as part of their background regimen. Therefore, the pharmacokinetic parameter estimates shown in Table 4 account for reductions in the pharmacokinetic parameters of etravirine due to co-administration of INTELENCE<span class="Sup">®</span> with darunavir/ritonavir.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">AUC<span class="Sub">12h</span> (ng∙h/mL)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Geometric Mean ± Standard Deviation</td>
<td class="Rrule" align="center">4522 ± 4710</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Median (Range)</td>
<td class="Rrule" align="center">4380 (458 – 59084)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">C<span class="Sub">0h</span> (ng/mL)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Geometric Mean ± Standard Deviation</td>
<td class="Rrule" align="center">297 ± 391</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Median (Range)</td>
<td class="Rrule" align="center">298 (2 – 4852)</td>
</tr>
</tbody>
</table>
<p>Note: The median protein binding adjusted EC50 for MT4 cells infected with HIV-1/IIIB in vitro equals 4 ng per mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics">Absorption and Bioavailability</span></p>
<p>Following oral administration, etravirine was absorbed with a T<span class="Sub">max</span> of about 2.5 to 4 hours. The absolute oral bioavailability of INTELENCE<span class="Sup">®</span> is unknown.</p>
<p>In healthy subjects, the absorption of etravirine is not affected by co-administration of oral ranitidine or omeprazole, drugs that increase gastric pH.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics">Effects of Food on Oral Absorption</span></p>
<p>The systemic exposure (AUC) to etravirine was decreased by about 50% when INTELENCE<span class="Sup">®</span> was administered under fasting conditions, as compared to when INTELENCE<span class="Sup">®</span> was administered following a meal. Therefore, INTELENCE<span class="Sup">®</span> should always be taken following a meal. Within the range of meals studied, the systemic exposures to etravirine were similar. The total caloric content of the various meals evaluated ranged from 345 kilocalories (17 grams fat) to 1160 kilocalories (70 grams fat) [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>Etravirine is about 99.9% bound to plasma proteins, primarily to albumin (99.6%) and alpha 1-acid glycoprotein (97.66% to 99.02%) <span class="Italics">in vitro</span>. The distribution of etravirine into compartments other than plasma (e.g., cerebrospinal fluid, genital tract secretions) has not been evaluated in humans.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p><span class="Italics">In vitro</span> experiments with human liver microsomes (HLMs) indicate that etravirine primarily undergoes metabolism by CYP3A, CYP2C9, and CYP2C19 enzymes. The major metabolites, formed by methyl hydroxylation of the dimethylbenzonitrile moiety, were at least 90% less active than etravirine against wild-type HIV in cell culture.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Italics">Elimination</span></p>
<p>After single dose oral administration of 800 mg <span class="Sup">14</span>C-etravirine, 93.7% and 1.2% of the administered dose of <span class="Sup">1</span><span class="Sup">4</span>C-etravirine was recovered in the feces and urine, respectively. Unchanged etravirine accounted for 81.2% to 86.4% of the administered dose in feces. Unchanged etravirine was not detected in urine. The mean (± standard deviation) terminal elimination half-life of etravirine was about 41 (± 20) hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Italics Underline">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Etravirine is primarily metabolized by the liver. The steady state pharmacokinetic parameters of etravirine were similar after multiple dose administration of INTELENCE<span class="Sup">®</span> to subjects with normal hepatic function (16 subjects), mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class A, 8 subjects), and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B, 8 subjects). The effect of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of etravirine has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B and/or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C Virus Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></p>
<p>Population pharmacokinetic analysis of the TMC125-C206 and TMC125-C216 trials showed reduced clearance for etravirine in HIV-1-infected subjects with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C virus co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Based upon the safety profile of INTELENCE<span class="Sup">®</span> [<span class="Italics">see <a href="#S6">Adverse Reactions (6)</a></span>], no dose adjustment is necessary in patients co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C virus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.3"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The pharmacokinetics of etravirine have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The results from a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study with <span class="Sup">14</span>C-etravirine showed that less than 1.2% of the administered dose of etravirine is excreted in the urine as metabolites. No unchanged drug was detected in the urine. As etravirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by hemodialysis or peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.4"></a><p></p>
<p class="First"><span class="Italics">Gender</span></p>
<p>No significant pharmacokinetic differences have been observed between males and females.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.5"></a><p></p>
<p class="First"><span class="Italics">Race</span></p>
<p>Population pharmacokinetic analysis of etravirine in HIV-infected subjects did not show an effect of race on exposure to etravirine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.6"></a><p></p>
<p class="First"><span class="Italics">Geriatric Patients</span></p>
<p>Population pharmacokinetic analysis in HIV-infected subjects showed that etravirine pharmacokinetics are not considerably different within the age range (18 to 77 years) evaluated [<span class="Italics">see <a href="#S8.5">Use in Specific Populations (8.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.7"></a><p></p>
<p class="First"><span class="Italics">Pediatric Patients</span></p>
<p>The pharmacokinetics of etravirine in 101 treatment-experienced HIV-1-infected pediatric subjects, 6 years to less than 18 years of age and weighing at least 16 kg showed that the administered weight-based dosages (approximately 5.2 mg per kg twice daily up to the adult recommended doses) resulted in etravirine exposure comparable to that in adults receiving INTELENCE<span class="Sup">®</span> 200 mg twice daily [<span class="Italics">see <a href="#S2.2">Dosage and Administration (2.2)</a></span>] when administered at a dose corresponding to 5.2 mg per kg twice daily. The population pharmacokinetic estimates for etravirine AUC<span class="Sub">12h</span> and C<span class="Sub">0h</span> are summarized in the table below.</p>
<a name="ifd6c550c-22fe-494a-8400-99f8b7554141"></a><table width="100%">
<caption><span>Population pharmacokinetic estimates for etravirine (all doses combined) in treatment-experienced HIV-1-infected pediatric subjects 6 years to less than 18 years of age (TMC125-C213)</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Parameter</th>
<th class="Rrule" align="center">N = 101</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">AUC<span class="Sub">12h</span> (ng•h/ml)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Geometric Mean ± Standard Deviation</td>
<td class="Rrule" align="center">3742 ± 4314</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Median (Range)</td>
<td class="Rrule" align="center">4499 (62 – 28865)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">C<span class="Sub">0h</span> (ng•h/ml)</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Geometric Mean ± Standard Deviation</td>
<td class="Rrule" align="center">205 ± 342</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Median (Range)</td>
<td class="Rrule" align="center">287 (2 – 2276)</td>
</tr>
</tbody>
</table>
<p>The pharmacokinetics of etravirine in pediatric subjects less than 6 years of age have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Italics">Drug Interactions</span></p>
<p>[<span class="Italics">See also <a href="#S7">Drug Interactions (7)</a></span>.]</p>
<p>Etravirine is a substrate of CYP3A, CYP2C9, and CYP2C19. Therefore, co-administration of INTELENCE<span class="Sup">®</span> with drugs that induce or inhibit CYP3A, CYP2C9, and CYP2C19 may alter the therapeutic effect or adverse reaction profile of INTELENCE<span class="Sup">®</span>.</p>
<p>Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein. Therefore, co-administration of drugs that are substrates of CYP3A, CYP2C9 and CYP2C19 or are transported by P-glycoprotein with INTELENCE<span class="Sup">®</span> may alter the therapeutic effect or adverse reaction profile of the co-administered drug(s).</p>
<p>Drug interaction studies were performed with INTELENCE<span class="Sup">®</span> and other drugs likely to be co-administered and some drugs commonly used as probes for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span>. The effects of co-administration of other drugs on the AUC, C<span class="Sub">max</span>, and C<span class="Sub">min</span> values of etravirine are summarized in Table 5 (effect of other drugs on INTELENCE<span class="Sup">®</span>). The effect of co-administration of INTELENCE<span class="Sup">®</span> on the AUC, C<span class="Sub">max</span>, and C<span class="Sub">min</span> values of other drugs are summarized in Table 6 (effect of INTELENCE<span class="Sup">®</span> on other drugs). For information regarding clinical recommendations, <span class="Italics">see <a href="#S7">Drug Interactions (7)</a></span>.</p>
<a name="table5"></a><table width="100%">
<caption><span>Table 5: Drug Interactions: Pharmacokinetic Parameters for Etravirine in the Presence of Co-administered Drugs</span></caption>
<col align="left" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2" valign="bottom">Co-administered Drug</th>
<th class="Rrule" align="center" rowspan="2" valign="bottom">Dose/Schedule of Co-administered Drug</th>
<th class="Rrule" align="center" rowspan="2" valign="bottom">N</th>
<th class="Rrule" align="center" rowspan="2" valign="bottom">Exposure</th>
<th class="Rrule" align="center" colspan="3" valign="bottom">Mean Ratio of <span class="Underline">Etravirine</span><br>Pharmacokinetic Parameters<br>90% CI; No Effect = 1.00</th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="bottom">C<span class="Sub">max</span>
</th>
<th class="Botrule Rrule" align="center" valign="bottom">AUC</th>
<th class="Botrule Rrule" align="center" valign="bottom">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="7">CI = Confidence Interval; N = number of subjects with data; N.A. = not available; ↑ = increase; ↓ = decrease; ↔ = no change; q.d. = once daily; b.i.d. = twice daily; q.a.m. = once daily in the morning</td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>The reference for etravirine exposure is the pharmacokinetic parameters of etravirine in the presence of darunavir/ritonavir.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Co-Administration With Protease Inhibitors (PIs)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Atazanavir</td>
<td class="Rrule" align="center">400 mg q.d.</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.47<br> (1.36–1.59)</td>
<td class="Rrule" align="center">1.50<br> (1.41–1.59)</td>
<td class="Rrule" align="center">1.58<br> (1.46–1.70)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Atazanavir/<br> ritonavir
                                       </td>
<td class="Rrule" align="center">300/100 mg q.d.</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.30<br> (1.17–1.44)</td>
<td class="Rrule" align="center">1.30<br> (1.18–1.44)</td>
<td class="Rrule" align="center">1.26<br> (1.12–1.42)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Darunavir/<br> ritonavir</td>
<td class="Rrule" align="center">600/100 mg b.i.d.</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.68<br> (0.57–0.82)</td>
<td class="Rrule" align="center">0.63<br> (0.54–0.73)</td>
<td class="Rrule" align="center">0.51<br> (0.44–0.61)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lopinavir/<br> ritonavir<br>(tablet)</td>
<td class="Rrule" align="center">400/100 mg b.i.d.</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.70<br>(0.64–0.78)</td>
<td class="Rrule" align="center">0.65<br>(0.59–0.71)</td>
<td class="Rrule" align="center">0.55<br>(0.49–0.62)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ritonavir</td>
<td class="Rrule" align="center">600 mg b.i.d.</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.68<br> (0.55–0.85)</td>
<td class="Rrule" align="center">0.54<br> (0.41–0.73)</td>
<td class="Rrule" align="center">N.A.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Saquinavir/<br> ritonavir<br>
</td>
<td class="Rrule" align="center">1000/100 mg b.i.d.</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.63<br> (0.53–0.75)</td>
<td class="Rrule" align="center">0.67<br> (0.56–0.80)</td>
<td class="Rrule" align="center">0.71<br> (0.58–0.87)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Tipranavir/<br> ritonavir</td>
<td class="Rrule" align="center">500/200 mg b.i.d.</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.29<br> (0.22–0.40)</td>
<td class="Rrule" align="center">0.24<br> (0.18–0.33)</td>
<td class="Rrule" align="center">0.18<br> (0.13–0.25)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Co-Administration With Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Didanosine</td>
<td class="Rrule" align="center">400 mg q.d.</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.16<br> (1.02–1.32)</td>
<td class="Rrule" align="center">1.11<br> (0.99–1.25)</td>
<td class="Rrule" align="center">1.05<br> (0.93–1.18)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Tenofovir disoproxil fumarate</td>
<td class="Rrule" align="center">300 mg q.d.</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.81<br> (0.75–0.88)</td>
<td class="Rrule" align="center">0.81<br> (0.75–0.88)</td>
<td class="Rrule" align="center">0.82<br> (0.73–0.91)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Co-Administration With CCR5 Antagonists</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Maraviroc</td>
<td class="Rrule" align="center">300 mg b.i.d.</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.05<br>(0.95–1.17)</td>
<td class="Rrule" align="center">1.06<br>(0.99–1.14)</td>
<td class="Rrule" align="center">1.08<br>(0.98–1.19)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Maraviroc (when co-administered with darunavir/ritonavir)<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="center">150/600/100 mg b.i.d.</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.08<br>(0.98–1.20)</td>
<td class="Rrule" align="center">1.00<br>(0.86–1.15)</td>
<td class="Rrule" align="center">0.81<br>(0.65–1.01)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Co-Administration With Integrase Strand Transfer Inhibitors</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Raltegravir</td>
<td class="Rrule" align="center">400 mg b.i.d.</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.04<br> (0.97–1.12)</td>
<td class="Rrule" align="center">1.10<br> (1.03–1.16)</td>
<td class="Rrule" align="center">1.17<br> (1.10–1.26)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Co-Administration With Other Drugs</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Atorvastatin</td>
<td class="Rrule" align="center">40 mg q.d.</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">0.97<br> (0.93–1.02)</td>
<td class="Rrule" align="center">1.02<br> (0.97–1.07)</td>
<td class="Rrule" align="center">1.10<br> (1.02–1.19)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Clarithromycin</td>
<td class="Rrule" align="center">500 mg b.i.d.</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.46<br> (1.38–1.56)</td>
<td class="Rrule" align="center">1.42<br> (1.34–1.50)</td>
<td class="Rrule" align="center">1.46<br> (1.36–1.58)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fluconazole</td>
<td class="Rrule" align="center">200 mg q.a.m.</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.75<br>(1.60–1.91)</td>
<td class="Rrule" align="center">1.86<br>(1.73–2.00)</td>
<td class="Rrule" align="center">2.09<br>(1.90–2.31)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Omeprazole</td>
<td class="Rrule" align="center">40 mg q.d.</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.17<br> (0.96–1.43)</td>
<td class="Rrule" align="center">1.41<br> (1.22–1.62)</td>
<td class="Rrule" align="center">N.A.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Paroxetine</td>
<td class="Rrule" align="center">20 mg q.d.</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.05<br> (0.96–1.15)</td>
<td class="Rrule" align="center">1.01<br> (0.93–1.10)</td>
<td class="Rrule" align="center">1.07<br> (0.98–1.17)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ranitidine</td>
<td class="Rrule" align="center">150 mg b.i.d.</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.94<br> (0.75–1.17)</td>
<td class="Rrule" align="center">0.86<br> (0.76–0.97)</td>
<td class="Rrule" align="center">N.A.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Rifabutin</td>
<td class="Rrule" align="center">300 mg q.d.</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.63<br> (0.53–0.74)</td>
<td class="Rrule" align="center">0.63<br> (0.54–0.74)</td>
<td class="Rrule" align="center">0.65<br> (0.56–0.74)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Voriconazole</td>
<td class="Rrule" align="center">200 mg b.i.d.</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.26<br>(1.16–1.38)</td>
<td class="Rrule" align="center">1.36<br>(1.25–1.47)</td>
<td class="Rrule" align="center">1.52<br>(1.41–1.64)</td>
</tr>
</tbody>
</table>
<a name="table6"></a><table width="100%">
<caption><span>Table 6: Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of INTELENCE<span class="Sup">®</span></span></caption>
<col align="left" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<col align="center" valign="top" width="14%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2" valign="bottom">Co-administered Drug</th>
<th class="Rrule" align="center" rowspan="2" valign="bottom">Dose/Schedule of Co-administered Drug</th>
<th class="Rrule" align="center" rowspan="2" valign="bottom">N</th>
<th class="Rrule" align="center" rowspan="2" valign="bottom">Exposure</th>
<th class="Rrule" align="center" colspan="3" valign="bottom">Mean Ratio of<br><span class="Underline">Co-administered Drug</span><br>Pharmacokinetic Parameters<br>90% CI; No effect = 1.00</th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="bottom">C<span class="Sub">max</span>
</th>
<th class="Botrule Rrule" align="center" valign="bottom">AUC</th>
<th class="Botrule Rrule" align="center" valign="bottom">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="7">CI = Confidence Interval; N = number of subjects with data; N.A. = not available; ↑ = increase; ↓ = decrease; ↔ = no change; q.d. = once daily ; b.i.d. = twice daily; q.a.m. = once daily in the morning</td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>compared to maraviroc 150 mg b.i.d.</dd>
</dl></td></tr>
</tfoot>
<tbody><tr class="Botrule First Last"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Co-Administration With Protease Inhibitors (PIs)</span></td></tr></tbody>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Atazanavir</td>
<td class="Rrule" align="center">400 mg q.d.</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.97<br> (0.73–1.29)</td>
<td class="Rrule" align="center">0.83<br> (0.63–1.09)</td>
<td class="Rrule" align="center">0.53<br> (0.38–0.73)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Atazanavir/<br> ritonavir</td>
<td class="Rrule" align="center">300/100 mg q.d.</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.97<br> (0.89–1.05)</td>
<td class="Rrule" align="center">0.86<br> (0.79–0.93)</td>
<td class="Rrule" align="center">0.62<br> (0.55–0.71)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Darunavir/<br> ritonavir</td>
<td class="Rrule" align="center">600/100 mg b.i.d.</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.11<br> (1.01–1.22)</td>
<td class="Rrule" align="center">1.15<br> (1.05–1.26)</td>
<td class="Rrule" align="center">1.02<br> (0.90–1.17)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fosamprenavir/<br> ritonavir</td>
<td class="Rrule" align="center">700/100 mg b.i.d.</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.62<br> (1.47–1.79)</td>
<td class="Rrule" align="center">1.69<br> (1.53–1.86)</td>
<td class="Rrule" align="center">1.77<br> (1.39–2.25)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lopinavir/<br> ritonavir 														<br>(tablet)</td>
<td class="Rrule" align="center">400/100 mg b.i.d.</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">0.89<br>(0.82–0.96)</td>
<td class="Rrule" align="center">0.87<br>(0.83–0.92)</td>
<td class="Rrule" align="center">0.80<br>(0.73–0.88)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Saquinavir/<br> ritonavir</td>
<td class="Rrule" align="center">1000/100 mg b.i.d.</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.00<br> (0.70–1.42)</td>
<td class="Rrule" align="center">0.95<br> (0.64–1.42)</td>
<td class="Rrule" align="center">0.80<br> (0.46–1.38)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Tipranavir/<br> ritonavir</td>
<td class="Rrule" align="center">500/200 mg b.i.d.</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.14<br> (1.02–1.27)</td>
<td class="Rrule" align="center">1.18<br> (1.03–1.36)</td>
<td class="Rrule" align="center">1.24<br> (0.96–1.59)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Co-Administration With Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Didanosine</td>
<td class="Rrule" align="center">400 mg q.d.</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">0.91<br> (0.58–1.42)</td>
<td class="Rrule" align="center">0.99<br> (0.79–1.25)</td>
<td class="Rrule" align="center">N.A.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Tenofovir disoproxil fumarate</td>
<td class="Rrule" align="center">300 mg q.d.</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.15<br> (1.04–1.27)</td>
<td class="Rrule" align="center">1.15<br> (1.09–1.21)</td>
<td class="Rrule" align="center">1.19<br> (1.13–1.26)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Co-Administration With CCR5 Antagonists</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Maraviroc</td>
<td class="Rrule" align="center">300 mg b.i.d.</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.40<br>(0.28–0.57)</td>
<td class="Rrule" align="center">0.47<br>(0.38–0.58)</td>
<td class="Rrule" align="center">0.61<br>(0.53–0.71)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Maraviroc (when co-administered with darunavir/ritonavir)<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="center">150/600/100 mg b.i.d.</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.77<br>(1.20–2.60)</td>
<td class="Rrule" align="center">3.10<br>(2.57–3.74)</td>
<td class="Rrule" align="center">5.27<br>(4.51–6.15)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Co-Administration With Integrase Strand Transfer Inhibitors</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Raltegravir</td>
<td class="Rrule" align="center">400 mg b.i.d.</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.89<br> (0.68–1.15)</td>
<td class="Rrule" align="center">0.90<br> (0.68–1.18)</td>
<td class="Rrule" align="center">0.66<br> (0.34–1.26)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Co-Administration With Other Drugs</span></td></tr>
<tr>
<td class="Lrule Rrule" align="left">Atorvastatin</td>
<td class="Rrule" align="center">40 mg q.d.</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">1.04<br> (0.84–1.30)</td>
<td class="Rrule" align="center">0.63<br> (0.58–0.68)</td>
<td class="Rrule" align="center">N.A.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">2-hydroxy-atorvastatin</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.76<br> (1.60–1.94)</td>
<td class="Rrule" align="center">1.27<br> (1.19–1.36)</td>
<td class="Rrule" align="center">N.A.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Buprenorphine</td>
<td class="Rrule" align="center">Individual dose regimen ranging from 4/1 mg to 16/4 mg q.d.</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.89<br> (0.76–1.05)</td>
<td class="Rrule" align="center">0.75<br> (0.66–0.84)</td>
<td class="Rrule" align="center">0.60<br> (0.52–0.68)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Norbuprenorphine</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.08<br> (0.95–1.23)</td>
<td class="Rrule" align="center">0.88<br> (0.81–0.96)</td>
<td class="Rrule" align="center">0.76<br> (0.67–0.87)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Clarithromycin</td>
<td class="Rrule" align="center">500 mg b.i.d.</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.66<br> (0.57–0.77)</td>
<td class="Rrule" align="center">0.61<br> (0.53–0.69)</td>
<td class="Rrule" align="center">0.47<br> (0.38–0.57)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">14-hydroxy-clarithromycin</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.33<br> (1.13–1.56)</td>
<td class="Rrule" align="center">1.21<br> (1.05–1.39)</td>
<td class="Rrule" align="center">1.05<br> (0.90–1.22)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Digoxin</td>
<td class="Rrule" align="center">0.5 mg single dose</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.19<br>(0.96–1.49)</td>
<td class="Rrule" align="center">1.18<br>(0.90–1.56)</td>
<td class="Rrule" align="center">N.A.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Ethinylestradiol</td>
<td class="Rrule" align="center">0.035 mg q.d.</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">1.33<br> (1.21–1.46)</td>
<td class="Rrule" align="center">1.22<br> (1.13–1.31)</td>
<td class="Rrule" align="center">1.09<br> (1.01–1.18)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Norethindrone</td>
<td class="Rrule" align="center">1 mg q.d.</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.05<br> (0.98–1.12)</td>
<td class="Rrule" align="center">0.95<br> (0.90–0.99)</td>
<td class="Rrule" align="center">0.78<br> (0.68–0.90)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fluconazole</td>
<td class="Rrule" align="center">200 mg q.a.m.</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">0.92<br>(0.85–1.00)</td>
<td class="Rrule" align="center">0.94<br>(0.88–1.01)</td>
<td class="Rrule" align="center">0.91<br>(0.84–0.98)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">R(-) Methadone</td>
<td class="Rrule" align="center">Individual dose regimen ranging from 60 to 130 mg/day</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.02<br> (0.96–1.09)</td>
<td class="Rrule" align="center">1.06<br> (0.99–1.13)</td>
<td class="Rrule" align="center">1.10<br> (1.02–1.19)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">S(+) Methadone</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">0.89<br> (0.83–0.97)</td>
<td class="Rrule" align="center">0.89<br> (0.82–0.96)</td>
<td class="Rrule" align="center"> 0.89<br> (0.81–0.98)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Paroxetine</td>
<td class="Rrule" align="center">20 mg q.d.</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">↔</td>
<td class="Rrule" align="center">1.06<br> (0.95–1.20)</td>
<td class="Rrule" align="center">1.03<br> (0.90–1.18)</td>
<td class="Rrule" align="center">0.87<br> (0.75–1.02)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Rifabutin</td>
<td class="Rrule" align="center">300 mg q.d.</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.90<br> (0.78–1.03)</td>
<td class="Rrule" align="center">0.83<br> (0.75–0.94)</td>
<td class="Rrule" align="center">0.76<br> (0.66–0.87)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">25-<span class="Italics">O</span>-desacetylrifabutin</td>
<td class="Rrule" align="center">300 mg q.d.</td>
<td class="Rrule" align="center">12<br>
</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.85<br> (0.72–1.00)</td>
<td class="Rrule" align="center">0.83<br> (0.74–0.92)</td>
<td class="Rrule" align="center">0.78<br> (0.70–0.87)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Sildenafil</td>
<td class="Rrule" align="center">50 mg single dose</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.55<br> (0.40–0.75)</td>
<td class="Rrule" align="center">0.43<br> (0.36–0.51)</td>
<td class="Rrule" align="center">N.A.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">N-desmethyl-sildenafil</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">↓</td>
<td class="Rrule" align="center">0.75<br> (0.59–0.96)</td>
<td class="Rrule" align="center">0.59<br> (0.52–0.68)</td>
<td class="Rrule" align="center">N.A.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Voriconazole</td>
<td class="Rrule" align="center">200 mg b.i.d.</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↑</td>
<td class="Rrule" align="center">0.95<br>(0.75–1.21)</td>
<td class="Rrule" align="center">1.14<br>(0.88–1.47)</td>
<td class="Rrule" align="center">1.23<br>(0.87–1.75)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="S12.4"></a><a name="section-11.4"></a><p></p>
<h2>12.4	Microbiology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.1"></a><p></p>
<p class="First"><span class="Italics">Mechanism of Action</span></p>
<p>Etravirine is an NNRTI of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus type 1 (HIV-1). Etravirine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. Etravirine does not inhibit the human DNA polymerases α, β, and γ.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.2"></a><p></p>
<p class="First"><span class="Italics">Antiviral Activity in Cell Culture</span></p>
<p>Etravirine exhibited activity against laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and clinical isolates of wild-type HIV-1 in acutely infected T-cell lines, human peripheral blood mononuclear cells, and human monocytes/macrophages with median EC<span class="Sub">50</span> values ranging from 0.9 to 5.5 nM (i.e., 0.4 to 2.4 ng per mL). Etravirine demonstrated antiviral activity in cell culture against a broad panel of HIV-1 group M isolates (subtype A, B, C, D, E, F, G) with EC<span class="Sub">50</span> values ranging from 0.29 to 1.65 nM and EC<span class="Sub">50</span> values ranging from 11.5 to 21.7 nM against group O primary isolates. Etravirine did not show antagonism when studied in combination with the following antiretroviral drugs—the NNRTIs delavirdine, efavirenz, and nevirapine; the N(t)RTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine; the PIs amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir; the fusion inhibitor enfuvirtide; the integrase strand transfer inhibitor raltegravir and the CCR5 co-receptor antagonist maraviroc.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.3"></a><p></p>
<p class="First"><span class="Underline">Resistance</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.3.1"></a><p></p>
<p class="First"><span class="Italics">In Cell Culture</span></p>
<p>Etravirine-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> were selected in cell culture originating from wild-type HIV-1 of different origins and subtypes, as well as NNRTI resistant HIV-1. Development of reduced susceptibility to etravirine typically required more than one substitution in reverse transcriptase of which the following were observed most frequently: L100I, E138K, E138G, V179I, Y181C, and M230I.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.3.2"></a><p></p>
<p class="First"><span class="Italics">In Treatment-Experienced Subjects</span></p>
<p>In the Phase 3 trials TMC125-C206 and TMC125-C216, substitutions that developed most commonly in subjects with virologic failure at Week 48 to the INTELENCE<span class="Sup">®</span>-containing regimen were V179F, V179I, and Y181C which usually emerged in a background of multiple other NNRTI resistance-associated substitutions. In all the trials conducted with INTELENCE<span class="Sup">®</span> in HIV-1 infected subjects, the following substitutions emerged most commonly: L100I, E138G, V179F, V179I, Y181C and H221Y. Other NNRTI-resistance associated substitutions which emerged on etravirine treatment in less than 10% of the virologic failure isolates included K101E/H/P, K103N/R, V106I/M, V108I, Y181I, Y188L, V189I, G190S/C, N348I and R356K. The emergence of NNRTI substitutions on etravirine treatment contributed to decreased susceptibility to etravirine with a median fold-change in etravirine susceptibility of 40-fold from reference and a median fold-change of 6-fold from baseline.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.4"></a><p></p>
<p class="First"><span class="Underline">Cross-Resistance</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.4.1"></a><p></p>
<p class="First"><span class="Italics">Site-Directed NNRTI Mutant Virus</span></p>
<p>Etravirine showed antiviral activity against 55 of 65 HIV-1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> (85%) with single amino acid substitutions at RT positions associated with NNRTI resistance, including the most commonly found K103N. The single amino acid substitutions associated with an etravirine reduction in susceptibility greater than 3-fold were K101A, K101P, K101Q, E138G, E138Q, Y181C, Y181I, Y181T, Y181V, and M230L, and of these, the greatest reductions were Y181I (13-fold change in EC<span class="Sub">50</span> value) and Y181V (17-fold change in EC<span class="Sub">50</span> value). Mutant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> containing a single NNRTI resistance associated substitution (K101P, K101Q, E138Q, or M230L) had cross-resistance between etravirine and efavirenz. The majority (39 of 61; 64%) of the NNRTI mutant viruses with 2 or 3 amino acid substitutions associated with NNRTI resistance had decreased susceptibility to etravirine (fold-change greater than 3). The highest levels of resistance to etravirine were observed for HIV-1 harboring a combination of substitutions V179F + Y181C (187 fold-change), V179F + Y181I (123 fold-change), or V179F + Y181C + F227C (888 fold-change).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.4.2"></a><p></p>
<p class="First"><span class="Italics">Clinical Isolate</span>s</p>
<p>Etravirine retained a fold-change less than or equal to 3 against 60% of 6171 NNRTI-resistant clinical isolates. In the same panel, the proportion of clinical isolates resistant to delavirdine, efavirenz and/or nevirapine (defined as a fold-change above their respective biological cutoff values in the assay) was 79%, 87%, and 95%, respectively. In TMC125-C206 and TMC125-C216, 34% of the baseline isolates had decreased susceptibility to etravirine (fold-change greater than 3) and 60%, 69%, and 78% of all baseline isolates were resistant to delavirdine, efavirenz, and nevirapine, respectively. Of subjects who received etravirine and were virologic failures in TMC125-C206 and TMC125-C216, 90%, 84%, and 96% of viral isolates obtained at the time of treatment failure were resistant to delavirdine, efavirenz, and nevirapine, respectively. Therefore, cross-resistance to delavirdine, efavirenz, and/or nevirapine is expected after virologic failure with an etravirine-containing regimen for the virologic failure isolates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.4.3"></a><p></p>
<p class="First"><span class="Italics">Treatment-naïve HIV</span>-<span class="Italics">1</span>-<span class="Italics">infected subjects in the Phase 3 trials for EDURANT (rilpivirine)</span></p>
<p>There are currently no clinical data available on the use of etravirine in subjects who experienced virologic failure on a rilpivirine-containing regimen. However, in the rilpivirine adult clinical development program, there was evidence of phenotypic cross-resistance between rilpivirine and etravirine. In the pooled analyses of the Phase 3 clinical trials for rilpivirine, 38 rilpivirine virologic failure subjects had evidence of HIV-1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> with genotypic and phenotypic resistance to rilpivirine. Of these subjects, 89% (34 subjects) of virologic failure isolates were cross-resistant to etravirine based on phenotype data. Consequently, it can be inferred that cross-resistance to etravirine is likely after virologic failure and development of rilpivirine resistance. Refer to the prescribing information for EDURANT (rilpivirine) for further information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4.4.4"></a><p></p>
<p class="First"><span class="Italics">Baseline Genotype/Phenotype and Virologic Outcome Analyses</span></p>
<p>In TMC125-C206 and TMC125-C216, the presence at baseline of the substitutions L100I, E138A, I167V, V179D, V179F, Y181I, Y181V, or G190S was associated with a decreased virologic response to etravirine. Additional substitutions associated with a decreased virologic response to etravirine when in the presence of 3 or more additional 2008 IAS-USA defined NNRTI substitutions include A98G, K101H, K103R, V106I, V179T, and Y181C. The presence of K103N, which was the most prevalent NNRTI substitution in TMC125-C206 and TMC125-C216 at baseline, did not affect the response in the INTELENCE<span class="Sup">®</span> arm. Overall, response rates to etravirine decreased as the number of baseline NNRTI substitutions increased (shown as the proportion of subjects achieving viral load less than 50 plasma HIV RNA copies per mL at Week 48) (Table 7).</p>
<a name="table7"></a><table width="100%">
<caption><span>Table 7: Proportion of Subjects with less than 50 HIV-1 RNA copies per mL at Week 48 by Baseline Number of IAS-USA-Defined NNRTI Substitutions in the Non-VF Excluded Population of the Pooled TMC125-C206 and TMC125-C216 Trials</span></caption>
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"># IAS-USA-Defined NNRTI substitutions<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a>
</th>
<th class="Rrule" align="center" colspan="2">Etravirine Arms<br>N = 561</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center">Re-Used/Not Used Enfuvirtide</th>
<th class="Rrule" align="center">De Novo Enfuvirtide</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>2008 IAS-USA defined substitutions = V90I, A98G, L100I, K101E/H/P, K103N, V106A/I/M, V108I, E138A, V179D/F/T, Y181C/I/V, Y188C/H/L, G190A/S, P225H, M230L</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="Bold">All ranges</span></td>
<td class="Rrule" align="center">61% (254/418)</td>
<td class="Rrule" align="center">76% (109/143)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">0</span></td>
<td class="Rrule" align="center">68% (52/76)</td>
<td class="Rrule" align="center">95% (20/21)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">1</span></td>
<td class="Rrule" align="center">67% (72/107)</td>
<td class="Rrule" align="center">77% (24/31)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">2</span></td>
<td class="Rrule" align="center">64% (75/118)</td>
<td class="Rrule" align="center">86% (38/44)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">3</span></td>
<td class="Rrule" align="center">55% (36/65)</td>
<td class="Rrule" align="center">62% (16/26)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">≥ 4</span></td>
<td class="Rrule" align="center">37% (19/52)</td>
<td class="Rrule" align="center">52% (11/21)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center" colspan="2">
<span class="Bold">Placebo Arms</span><br><span class="Bold">N = 592</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="Bold">All ranges</span></td>
<td class="Rrule" align="center">34% (147/435)</td>
<td class="Rrule" align="center">59% (93/157)</td>
</tr>
</tbody>
</table>
<p>Response rates assessed by baseline etravirine phenotype are shown in Table 8. These baseline phenotype groups are based on the select subject populations in TMC125-C206 and TMC125-C216 and are not meant to represent definitive clinical susceptibility breakpoints for INTELENCE<span class="Sup">®</span>. The data are provided to give clinicians information on the likelihood of virologic success based on pre-treatment susceptibility to etravirine in treatment-experienced patients.</p>
<a name="table8"></a><table width="100%">
<caption><span>Table 8: Proportion of Subjects with less than 50 HIV-1 RNA copies per mL at Week 48 by Baseline Phenotype and Enfuvirtide Use in the Pooled TMC125-C206 and TMC125-C216 Trials<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left">Etravirine Fold Change</th>
<th class="Rrule" align="center" colspan="3">Etravirine Arms<br>N = 559</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Re-Used/Not Used Enfuvirtide</th>
<th class="Rrule" align="center">De Novo Enfuvirtide</th>
<th class="Rrule" align="center">Clinical Response Range</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Non-VF excluded analysis</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">All ranges</span></td>
<td class="Rrule" align="center">61% (253/416)</td>
<td class="Rrule" align="center">76% (109/143)</td>
<td class="Rrule" align="center">Overall Response</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">0 – 3</span></td>
<td class="Rrule" align="center">69% (188/274)</td>
<td class="Rrule" align="center">83% (75/90)</td>
<td class="Rrule" align="center">Higher than Overall Response</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">&gt; 3 – 13</span></td>
<td class="Rrule" align="center">50% (39/78)</td>
<td class="Rrule" align="center">66% (25/38)</td>
<td class="Rrule" align="center">Lower than Overall Response</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">&gt; 13</span></td>
<td class="Rrule" align="center">41% (26/64)</td>
<td class="Rrule" align="center">60% (9/15)</td>
<td class="Rrule" align="center">Lower than Overall Response</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="center" colspan="3">
<span class="Bold">Placebo Arms</span><br><span class="Bold">N = 583</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">All ranges</span></td>
<td class="Rrule" align="center">34% (145/429)</td>
<td class="Rrule" align="center">60% (92/154)</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<p>The proportion of virologic responders (viral load less than 50 HIV-1 RNA copies per mL) by the phenotypic susceptibility score (PSS) of the background therapy, including enfuvirtide, is shown in Table 9.</p>
<a name="table9"></a><table width="80%">
<caption><span>Table 9: Virologic Response (Viral Load less than 50 HIV-1 RNA copies per mL) at Week 48 by Phenotypic Susceptibility Score in the Non-VF Excluded Population of TMC125-C206 and TMC125-C216 Trials (Pooled Analysis)</span></caption>
<col align="center" valign="middle" width="34%">
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center">INTELENCE<span class="Sup">®</span> + BR<br>N=559</th>
<th class="Rrule" align="center">Placebo + BR<br>N=586</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>The phenotypic susceptibility score (PSS) was defined as the total number of active antiretroviral drugs in the background therapy to which a subject's baseline viral isolate showed sensitivity in phenotypic resistance tests. Each drug in the background therapy was scored as a '1' or '0' based on whether the viral isolate was considered susceptible or resistant to that drug, respectively. In the calculation of the PSS, darunavir was counted as a sensitive antiretroviral if the FC was less than or equal to 10; enfuvirtide was counted as a sensitive antiretroviral if it had not been used previously. INTELENCE<span class="Sup">®</span> was not included in this calculation.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">
<span class="Bold">PSS</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">0</td>
<td class="Rrule" align="center">43% (40/93)</td>
<td class="Rrule" align="center">5% (5/95)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">1</td>
<td class="Rrule" align="center">61% (125/206)</td>
<td class="Rrule" align="center">28% (64/226)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">77% (114/149)</td>
<td class="Rrule" align="center">59% (97/165)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">≥ 3</td>
<td class="Rrule" align="center">75% (83/111)</td>
<td class="Rrule" align="center">72% (72/100)</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis</span></p>
<p>Etravirine was evaluated for carcinogenic potential by oral gavage administration to mice and rats for up to approximately 104 weeks. Daily doses of 50, 200 and 400 mg per kg were administered to mice and doses of 70, 200 and 600 mg per kg were administered to rats in the initial period of approximately 41 to 52 weeks. The high and middle doses were subsequently adjusted due to tolerability and reduced by 50% in mice and by 50 to 66% in rats to allow for completion of the studies. In the mouse study, statistically significant increases in the incidences of hepatocellular carcinoma and incidences of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> or carcinomas combined were observed in treated females. In the rat study, no statistically significant increases in tumor findings were observed in either sex. The relevance of these <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumor</span> findings in mice to humans is not known. Because of tolerability of the formulation in these rodent studies, maximum systemic drug exposures achieved at the doses tested were lower than those in humans at the clinical dose (400 mg per day), with animal vs. human AUC ratios being 0.6-fold (mice) and 0.2–0.7-fold (rats).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Bold">Mutagenesis</span></p>
<p>Etravirine tested negative in the <span class="Italics">in vitro</span> Ames reverse mutation assay, <span class="Italics">in vitro</span> chromosomal aberration assay in human lymphocyte, and <span class="Italics">in vitro</span> clastogenicity mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, tested in the absence and presence of a metabolic activation system. Etravirine did not induce chromosomal damage in the <span class="Italics">in vivo</span> micronucleus test in mice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Bold">Impairment of Fertility</span></p>
<p>No effects on fertility and early embryonic development were observed when etravirine was tested in rats at maternal doses up to 500 mg per kg per day, resulting in systemic drug exposure up to the recommended human dose (400 mg per day).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Treatment-Experienced Adult Subjects</h2>
<p class="First">The clinical efficacy of INTELENCE<span class="Sup">®</span> is derived from the analyses of 48-week data from 2 ongoing, randomized, double-blinded, placebo-controlled, Phase 3 trials, TMC125-C206 and TMC125-C216 (DUET-1 and DUET-2). These trials are identical in design and the results below are pooled data from the two trials.</p>
<p>TMC125-C206 and TMC125-C216 are Phase 3 studies designed to evaluate the safety and antiretroviral activity of INTELENCE<span class="Sup">®</span> in combination with a background regimen (BR) as compared to placebo in combination with a BR. Eligible subjects were treatment-experienced HIV-1-infected patients with plasma HIV-1 RNA greater than 5000 copies per mL while on an antiretroviral regimen for at least 8 weeks. In addition, subjects had 1 or more NNRTI resistance-associated mutations at screening or from prior genotypic analysis, and 3 or more of the following primary PI mutations at screening: D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, V82A/F/L/S/T, I84V, N88S, or L90M. Randomization was stratified by the intended use of enfuvirtide (ENF) in the BR, previous use of darunavir/ritonavir (DRV/rtv), and screening viral load. Virologic response was defined as HIV-1 RNA less than 50 copies per mL at Week 48.</p>
<p>All study subjects received DRV/rtv as part of their BR, and at least 2 other investigator-selected antiretroviral drugs (N[t]RTIs with or without ENF). Of INTELENCE<span class="Sup">®</span>-treated subjects, 25.5% used ENF for the first time (<span class="Italics">de novo</span>) and 20.0% re-used ENF. Of placebo-treated subjects, 26.5% used <span class="Italics">de novo</span> ENF and 20.4% re-used ENF.</p>
<p>In the pooled analysis for TMC125-C206 and TMC125-C216, demographics and baseline characteristics were balanced between the INTELENCE<span class="Sup">®</span> arm and the placebo arm. Table 10 displays selected demographic and baseline disease characteristics of the subjects in the INTELENCE<span class="Sup">®</span> and placebo arms.</p>
<a name="table10"></a><table width="100%">
<caption><span>Table 10: Demographic and Baseline Disease Characteristics of Subjects in the TMC125-C206 and TMC125-C216 Trials (Pooled Analysis)</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Pooled TMC125-C206 and TMC125-C216 Trials</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">INTELENCE<span class="Sup">®</span> + BR<br>N=599</th>
<th class="Rrule" align="center">Placebo + BR<br>N=604</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">RAMs = Resistance-Associated Mutations, BR=background regimen<br> FC = fold change in EC<span class="Sub">50</span><br>
</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>IAS-USA primary PI mutations [August/September 2007]: D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, I54L/M, L76V, V82A/F/L/S/T, I84V, N88S, L90M</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Tibotec NNRTI RAMs [June 2008]: A98G, V90I,  L100I, K101E/H/P/Q, K103H/N/S/T, V106A/M/I, V108I, E138A/G/K/Q, V179D/E/F/G/I/T, Y181C/I/V, Y188C/H/L, V189I, G190A/C/E/Q/S, H221Y, P255H, F227C/L, M230I/L, P236L, K238N/T, Y318F</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">‡</a></dt>
<dd>The PSS was calculated for the background therapy (as determined on Day 7). Percentages are based on the number of subjects with available phenotype data. For fusion inhibitors (enfuvirtide), subjects were considered resistant if the drug was used in previous therapy up to baseline. INTELENCE<span class="Sup">®</span> is not included in this calculation.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Demographic Characteristics</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median Age, years (range)<br>
</td>
<td class="Rrule" align="center">46<br> (18–77)</td>
<td class="Rrule" align="center">45<br> (18–72)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Sex</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Male</td>
<td class="Rrule" align="center">90.0%</td>
<td class="Rrule" align="center">88.6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Female</td>
<td class="Rrule" align="center">10.0%</td>
<td class="Rrule" align="center">11.4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Race</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  White</td>
<td class="Rrule" align="center">70.1%</td>
<td class="Rrule" align="center">69.8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Black</td>
<td class="Rrule" align="center">13.2%</td>
<td class="Rrule" align="center">13.0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Hispanic</td>
<td class="Rrule" align="center">11.3%</td>
<td class="Rrule" align="center">12.2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Asian</td>
<td class="Rrule" align="center">1.3%</td>
<td class="Rrule" align="center">0.6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Other</td>
<td class="Rrule" align="center">4.1%</td>
<td class="Rrule" align="center">4.5%</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Baseline Disease Characteristics</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median Baseline Plasma HIV-1 RNA (range), log<span class="Sub">10</span> copies/mL</td>
<td class="Rrule" align="center">4.8<br> (2.7–6.8)</td>
<td class="Rrule" align="center">4.8<br> (2.2–6.5)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Percentage of Subjects with Baseline Viral Load:</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 30,000 copies/mL</td>
<td class="Rrule" align="center">27.5%</td>
<td class="Rrule" align="center">28.8%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  ≥ 30,000 copies/mL and</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 100,000 copies/mL</td>
<td class="Rrule" align="center">34.4%</td>
<td class="Rrule" align="center">35.3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  ≥ 100,000 copies/mL</td>
<td class="Rrule" align="center">38.1%</td>
<td class="Rrule" align="center">35.9%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median Baseline CD4+ Cell Count (range), cells/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center">99<br> (1–789)</td>
<td class="Rrule" align="center">109<br> (0–912)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Percentage of Subjects with Baseline CD4+ Cell Count:</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  &lt; 50 cells/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center">35.6%</td>
<td class="Rrule" align="center">34.7%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  ≥ 50 cells/mm<span class="Sup">3</span> and &lt; 200 cells/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center">34.8%</td>
<td class="Rrule" align="center">34.5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  ≥ 200 cells/mm<span class="Sup">3</span>
</td>
<td class="Rrule" align="center">29.6%</td>
<td class="Rrule" align="center">30.8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median (range) Number of Primary PI Mutations<a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">4<br> (0–7)</td>
<td class="Rrule" align="center">4<br> (0–8)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Percentage of Subjects with Previous Use of NNRTIs:</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  0</td>
<td class="Rrule" align="center">8.2%</td>
<td class="Rrule" align="center">7.9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  1</td>
<td class="Rrule" align="center">46.9%</td>
<td class="Rrule" align="center">46.7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  &gt;1</td>
<td class="Rrule" align="center">44.9%</td>
<td class="Rrule" align="center">45.4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Percentage of Subjects with Previous Use of the following NNRTIs:</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Efavirenz</td>
<td class="Rrule" align="center">70.3%</td>
<td class="Rrule" align="center">72.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Nevirapine</td>
<td class="Rrule" align="center">57.1%</td>
<td class="Rrule" align="center">58.6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Delavirdine</td>
<td class="Rrule" align="center">13.7%</td>
<td class="Rrule" align="center">12.6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median (range) Number of NNRTI RAMs<a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a>
</td>
<td class="Rrule" align="center">2<br> (0–8)</td>
<td class="Rrule" align="center">2<br> (0–7)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Median Fold Change of the Virus for the Following NNRTIs:</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Delavirdine</td>
<td class="Rrule" align="center">27.3</td>
<td class="Rrule" align="center">26.1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Efavirenz</td>
<td class="Rrule" align="center">63.9</td>
<td class="Rrule" align="center">45.4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Etravirine</td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">1.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Nevirapine</td>
<td class="Rrule" align="center">74.3</td>
<td class="Rrule" align="center">74.0</td>
</tr>
<tr class="Botrule" valign="bottom">
<td class="Lrule Rrule" align="left">Percentage of Subjects with Previous Use of a Fusion Inhibitor</td>
<td class="Rrule" align="center">39.6%</td>
<td class="Rrule" align="center">42.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Percentage of Subjects with a Phenotypic Sensitivity Score (PSS) for the background therapy <a name="footnote-reference-13" href="#footnote-13" class="Sup">‡</a> of:</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">0</td>
<td class="Rrule" align="center">17.0%</td>
<td class="Rrule" align="center">16.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">1</td>
<td class="Rrule" align="center">36.5%</td>
<td class="Rrule" align="center">38.7%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">2</td>
<td class="Rrule" align="center">26.9%</td>
<td class="Rrule" align="center">27.8%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">≥ 3</td>
<td class="Rrule" align="center">19.7%</td>
<td class="Rrule" align="center">17.3%</td>
</tr>
</tbody>
</table>
<p>Efficacy at Week 48 for subjects in the INTELENCE<span class="Sup">®</span> and placebo arms for the pooled TMC125-C206 and TMC125-C216 study populations are shown in Table 11.</p>
<a name="table11"></a><table width="100%">
<caption><span>Table 11: Outcomes of Treatment at Week 48 of the TMC125-C206 and TMC125-C216 Trials (Pooled Analysis)</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">Pooled TMC125-C206 and TMC125-C216 Trials</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">INTELENCE<span class="Sup">®</span> + BR<br>N=599</th>
<th class="Rrule" align="center">Placebo + BR<br>N=604</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">BR=background regimen</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Virologic Responders at Week 48<br> Viral Load &lt; 50 HIV-1 RNA copies/mL </td>
<td class="Rrule" align="center">359 (60%)</td>
<td class="Rrule" align="center">232 (38%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Virologic Failures (VF) at Week 48<br> Viral Load ≥ 50 HIV-1 RNA copies/mL </td>
<td class="Rrule" align="center">123 (21%)</td>
<td class="Rrule" align="center">201 (33%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Rrule" align="center">11 (2%)</td>
<td class="Rrule" align="center">19 (3%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Discontinuations before Week 48:</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  due to VF</td>
<td class="Rrule" align="center">58 (10%)</td>
<td class="Rrule" align="center">110 (18%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  due to Adverse Events</td>
<td class="Rrule" align="center">31 (5%)</td>
<td class="Rrule" align="center">14 (2%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  due to other reasons</td>
<td class="Rrule" align="center">17 (3%)</td>
<td class="Rrule" align="center">28 (5%)</td>
</tr>
</tbody>
</table>
<p>At Week 48, 70.8% of INTELENCE<span class="Sup">®</span>-treated subjects achieved HIV-1 RNA less than 400 copies per mL as compared to 46.4% of placebo-treated subjects. The mean decrease in plasma HIV-1 RNA from baseline to Week 48 was -2.23 log<span class="Sub">10</span> copies per mL for INTELENCE<span class="Sup">®</span>-treated subjects and -1.46 log<span class="Sub">10</span> copies per mL for placebo-treated subjects. The mean CD4+ cell count increase from baseline for INTELENCE<span class="Sup">®</span>-treated subjects was 96 cells per mm<span class="Sup">3</span> and 68 cells per mm<span class="Sup">3</span> for placebo-treated subjects.</p>
<p>Of the study population who either re-used or did not use ENF, 57.4% of INTELENCE<span class="Sup">®</span>-treated subjects and 31.7% of placebo-treated subjects achieved HIV-1 RNA less than 50 copies per mL. Of the study population using ENF <span class="Italics">de novo,</span> 67.3% of INTELENCE<span class="Sup">®</span>-treated subjects and 57.2% of placebo-treated subjects achieved HIV-1 RNA less than 50 copies per mL.</p>
<p>Treatment-emergent CDC category C events occurred in 4% of INTELENCE<span class="Sup">®</span>-treated subjects and 8.4% of placebo-treated subjects.</p>
<p>Study TMC125-C227 was a randomized, exploratory, active-controlled, open-label, Phase 2b trial. Eligible subjects were treatment-experienced, PI-naïve HIV-1-infected patients with genotypic evidence of NNRTI resistance at screening or from prior genotypic analysis. The virologic response was evaluated in 116 subjects who were randomized to INTELENCE<span class="Sup">®</span> (59 subjects) or an investigator-selected PI (57 subjects), each given with 2 investigator-selected N(t)RTIs. INTELENCE<span class="Sup">®</span>-treated subjects had lower antiviral responses associated with reduced susceptibility to the N(t)RTIs and to INTELENCE<span class="Sup">®</span> as compared to the control PI-treated subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2        Treatment-Experienced Pediatric Subjects (6 years to less than 18 years of age)</h2>
<p class="First">TMC125-C213, a single-arm, Phase 2 trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of INTELENCE<span class="Sup">®</span> enrolled 101 antiretroviral treatment-experienced HIV-1 infected pediatric subjects 6 years to less than 18 years of age and weighing at least 16 kg. Subjects eligible for this trial were on an antiretroviral regimen with confirmed plasma HIV-1 RNA of at least 500 copies per mL and viral susceptibility to INTELENCE<span class="Sup">®</span> at screening.</p>
<p>The median baseline plasma HIV-1 RNA was 3.9 log<span class="Sub">10</span> copies per mL, and the median baseline CD4 cell count was 385 × 10<span class="Sup">6</span> cells per mm<span class="Sup">3</span>.</p>
<p>At Week 24, 52% of all pediatric subjects had HIV-1 RNA less than 50 copies per mL. The proportion of pediatric subjects with HIV-1 RNA less than 400 copies per mL was 67%. The mean CD4 cell count increase from baseline was 112 × 10<span class="Sup">6</span> cells per mm<span class="Sup">3</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><br></p>
<p>INTELENCE<span class="Sup">®</span> 100 mg tablets are supplied as white to off-white, oval tablets containing 100 mg of etravirine. Each tablet is debossed with "TMC125" on one side and "100" on the other side.</p>
<a name="i456b1014-4410-4c1f-8edb-7bc2f097b72d"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 120<br>
</td>
<td>NDC 54868-5864-0<br>
</td>
</tr></tbody></table>
<p>INTELENCE<span class="Sup">®</span> 200 mg tablets are supplied as white to off-white, biconvex, oblong tablets containing 200 mg of etravirine. Each tablet is  debossed with "T200" on one side.</p>
<a name="idf9b1db9-ee54-4a47-890d-1b6e7081eb9e"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>Bottles of 60<br>
</td>
<td>NDC 54868-6368-0<br>
</td>
</tr></tbody></table>
<br><div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store INTELENCE<span class="Sup">®</span> tablets at 25°C (77°F); with excursions permitted to 15°to 30°C (59°to 86°F) [see USP controlled room temperature]. Store in the original bottle. Keep the bottle tightly closed in order to protect from moisture. Do not remove the desiccant pouches.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17           PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <a href="#PPI">FDA-approved patient labeling (Patient Information)</a>.</p>
<p>A statement to patients and healthcare providers is included on the product's bottle label: <span class="Bold">ALERT: Find out about medicines that should NOT be taken with INTELENCE<span class="Sup">®</span> from your healthcare provider.</span> A Patient Package Insert for INTELENCE<span class="Sup">®</span> is available for patient information.</p>
<p>Patients should be informed that INTELENCE<span class="Sup">®</span> is not a cure for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> and that they may continue to develop <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> and other complications associated with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>. Patients should be told that sustained decreases in plasma HIV RNA have been associated with a reduced risk of progression to AIDS and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients should remain under the care of a physician while using INTELENCE<span class="Sup">®</span>.</p>
<p>Patients should be advised to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others. Patients should be advised to practice safe sex and to use latex or polyurethane condoms to lower the chance of sexual contact with any body fluids such as semen, vaginal secretions or blood. Patients should also be advised to never re-use or share needles or other injection equipment, or share personal items that can have blood or body fluids on them, such as toothbrushes and razor blades.</p>
<p>Patients should be advised to take INTELENCE<span class="Sup">®</span> following a meal twice a day as prescribed. The type of food does not affect the exposure to etravirine.</p>
<p>Patients should be instructed to swallow the INTELENCE<span class="Sup">®</span> tablet(s) whole with a liquid such as water. Patients should be instructed not to chew the tablets. Patients who are unable to swallow the INTELENCE<span class="Sup">®</span> tablet(s) whole may disperse the tablet(s) in a glass of water. The patient should be instructed to do the following:</p>
<ul class="Disc">
<li>place the tablet(s) in 5 mL   (1 teaspoon) of water, or at least enough liquid to cover the   medication,</li>
<li>stir well until the water looks milky,</li>
<li>if desired, add more water or alternatively orange   juice or milk (patients should not place the tablets in orange juice or   milk without first adding water). The use of grapefruit   juice or warm (greater than 104°F; greater than 40°C) or carbonated beverages should be avoided.</li>
<li>drink it immediately,</li>
<li>rinse the glass several times with water, orange   juice, or milk and completely swallow the rinse each time to make sure the   patient takes the entire dose.</li>
</ul>
<p>INTELENCE<span class="Sup">®</span> must always be used in combination with other antiretroviral drugs. Patients should not alter the dose of INTELENCE<span class="Sup">®</span> or discontinue therapy with INTELENCE<span class="Sup">®</span> without consulting their physician.</p>
<p>If the patient misses a dose of INTELENCE<span class="Sup">®</span> within 6 hours of the time it is usually taken, the patient should take INTELENCE<span class="Sup">®</span> following a meal as soon as possible, and then take the next dose of INTELENCE<span class="Sup">®</span> at the regularly scheduled time. If a patient misses a dose of INTELENCE<span class="Sup">®</span> by more than 6 hours of the time it is usually taken, the patient should not take the missed dose and simply resume the usual dosing schedule. Inform the patient that he or she should not take more or less than the prescribed dose of INTELENCE<span class="Sup">®</span> at any one time.</p>
<p>INTELENCE<span class="Sup">®</span> may interact with many drugs; therefore, patients should be advised to report to their healthcare provider the use of any other prescription or nonprescription medication or herbal products, including St. John's wort.</p>
<p>Patients should be informed that severe and potentially life-threatening <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> has been reported with INTELENCE<span class="Sup">®</span>. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> has been reported most commonly in the first 6 weeks of therapy. Patients should be advised to immediately contact their healthcare provider if they develop <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Instruct patients to immediately stop taking INTELENCE<span class="Sup">®</span> and seek medical attention if they develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> associated with any of the following symptoms as it may be a sign of a more serious reaction such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> or severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, generally ill feeling, extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="43530620" conceptname="Oral lesion">oral lesions</span>, <span class="product-label-link" type="condition" conceptid="376709" conceptname="Discharge of eye">eye inflammation</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the eyes, lips, mouth, breathing difficulty, and/or signs and symptoms of liver problems (e.g., yellowing of your skin or whites of your eyes, dark or tea colored urine, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> colored stools/bowel movements, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, loss of appetite, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, aching or sensitivity on your right side below your ribs). Patients should understand that if severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurs, they will be closely monitored, laboratory tests will be ordered and appropriate therapy will be initiated.</p>
<p>Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy, including INTELENCE<span class="Sup">®</span>, and that the cause and long-term health effects of these conditions are not known at this time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Product of Belgium<br>Finished Product Manufactured by:<br>Janssen Cilag S.p.A., Latina, Italy<br>Manufactured for:<br>Janssen Therapeutics, Division of Janssen Products, LP, Titusville NJ 08560</p>
<p>© Janssen Pharmaceuticals, Inc. 2008<br></p>
<br><p><br></p>
<p><span class="Bold">Distributed by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma    74146<br></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="PPI"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span><br><span class="Bold">INTELENCE<span class="Sup">®</span></span> (in-tel-ence)<br>(etravirine) tablets</p>
<p><span class="Bold">Important: Ask your doctor or pharmacist about medicines that should not be taken with INTELENCE<span class="Sup">®</span></span>. For more information, see the section "<a href="#DOC">What should I tell my doctor before taking INTELENCE</a><span class="Sup">®</span>?".</p>
<p>Read this Patient Information before you start taking INTELENCE<span class="Sup">®</span> and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. You and your doctor should discuss your treatment with INTELENCE<span class="Sup">®</span> when you start taking it and at regular checkups. You should not change or stop treatment without first talking with your doctor.</p>
<p><span class="Bold">What is INTELENCE<span class="Sup">®</span>?</span></p>
<ul class="Disc">
<li>
<span class="Bold">INTELENCE<span class="Sup">®</span> is a prescription HIV medicine that:</span><ul class="Circle">
<li>is used with other HIV   medicines to treat HIV (Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults   and children 6 years of age and older. HIV is the virus that   causes AIDS (<span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immune Deficiency Syndrome</span>). INTELENCE<span class="Sup">®</span> is   a type of HIV medicine called a non-nucleoside reverse transcriptase   inhibitor (NNRTI).</li>
<li>is used in people who are   already taking or have taken NNRTI and other HIV medicines and these   medicines are not controlling their <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>.</li>
</ul>
</li>
<li>It is not known if INTELENCE<span class="Sup">®</span> is safe and effective in children less than 6 years of age.</li>
</ul>
<p>When used with other HIV medicines, INTELENCE<span class="Sup">®</span> may:</p>
<ol>
<li>Reduce the amount of HIV in your blood (called "viral load").</li>
<li>Help increase the number of CD4 (T) cells in your blood which help fight off other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.<br>Reducing the amount of HIV and increasing the CD4 (T) cell count may improve your immune system. This may reduce your risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that can happen when your immune system is weak (<span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>).</li>
</ol>
<p><span class="Bold">INTELENCE<span class="Sup">®</span> does not cure <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> or AIDS.</span></p>
<p>You must stay on continuous HIV therapy to control <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> and decrease HIV-related illnesses.</p>
<p>Avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others:</p>
<ul>
<li><span class="Bold">Do not share or re-use needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
</ul>
<p>Ask your doctor if you have any questions on how to prevent passing HIV to other people.</p>
<p><span class="Bold">What should I tell my doctor before taking INTELENCE<span class="Sup">®</span>?</span></p>
<p><span class="Bold">Before taking INTELENCE<span class="Sup">®</span> tell your doctor if you:</span></p>
<ul>
<li>have had or currently have liver problems, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C.</li>
<li>have any other medical conditions.</li>
<li>are pregnant or plan to become pregnant. It is not known if INTELENCE<span class="Sup">®</span> will harm your unborn baby.<br><span class="Bold">Pregnancy Registry:</span> There is a pregnancy registry for women who take antiviral medicines during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your doctor about how you can take part in this registry.</li>
<li>are breastfeeding or plan to breastfeed. Do not breastfeed if you take INTELENCE<span class="Sup">®</span>. You should not breastfeed if you have HIV because of the risk of passing HIV to your baby. Talk with your doctor about the best way to feed your baby.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and nonprescription medicines, vitamins, and herbal supplements, including St. John's wort (<span class="Italics">Hypericum perforatum</span>). <span class="Bold">Some medicines may interact with INTELENCE<span class="Sup">®</span>.</span></p>
<p><span class="Bold">INTELENCE<span class="Sup">®</span> may affect the way other medicines work, and other medicines may affect how INTELENCE<span class="Sup">®</span> works. Taking INTELENCE<span class="Sup">®</span> and certain other medicines may cause serious side effects. </span>If you take certain medicines with INTELENCE<span class="Bold"><span class="Sup">®</span></span>, then the amount of INTELENCE<span class="Bold"><span class="Sup">®</span></span> in your body may be too low and INTELENCE<span class="Bold"><span class="Sup">®</span></span> may not work to help reduce your <span class="product-label-link" type="condition" conceptid="4201046" conceptname="HIV viral load">HIV viral load</span>. The HIV virus in your body may become resistant to INTELENCE<span class="Bold"><span class="Sup">®</span></span> or other HIV medicines that are like it.</p>
<p><span class="Bold">Tell your doctor if you take other HIV medicines.</span> Some HIV medicines should not be taken with INTELENCE<span class="Bold"><span class="Sup">®</span>.</span></p>
<p>Tell your doctor if you take:</p>
<ul>
<li>an antiarrhythmic to treat abnormal heart rhythms-amiodarone (Cordarone<span class="Sup">®</span>, Pacerone<span class="Sup">®</span>), bepridil (Vascor<span class="Sup">®</span>), digoxin (Lanoxin<span class="Sup">®</span>), disopyramide (Norpace<span class="Sup">®</span>), flecainide (Tambocor™), lidocaine (LidoPen<span class="Sup">®</span>, Xylocaine<span class="Sup">®</span>), mexiletine (Mexitil<span class="Sup">®</span>), propafenone (Rythmol SR<span class="Sup">®</span>), quinidine (Duraquin<span class="Sup">®</span>, Quinaglute<span class="Sup">®</span>)</li>
<li>an anticoagulant to prevent blood clots-warfarin (Coumadin<span class="Sup">®</span>)</li>
<li>an anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicine to treat <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> or prevent <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>-carbamazepine (Tegretol<span class="Sup">®</span>, Tegretol-XR<span class="Sup">®</span>, Carbatrol<span class="Sup">®</span>, Equetro<span class="Sup">®</span>, Teril<span class="Sup">®</span>, Epitol<span class="Sup">®</span>), phenobarbital (Luminal<span class="Sup">®</span>, Solfoton<span class="Sup">®</span>), phenytoin (Dilantin<span class="Sup">®</span>, Dilantin-125<span class="Sup">®</span>, Phenytek<span class="Sup">®</span>)</li>
<li>an antifungal to treat a <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>-fluconazole (Diflucan<span class="Sup">®</span>), itraconazole (Onmel<span class="Sup">®</span>, Sporanox<span class="Sup">®</span>), ketoconazole (Nizoral<span class="Sup">®</span>), posaconazole (Noxafil<span class="Sup">®</span>), voriconazole (Vfend<span class="Sup">®</span>)</li>
<li>an anti-infective to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>-clarithromycin (Biaxin<span class="Sup">®</span>, Biaxin XL<span class="Sup">®</span>)</li>
<li>an antimycobacterial to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, including <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB)-rifabutin (Mycobutin<span class="Sup">®</span>), rifampin (Rifadin<span class="Sup">®</span>, Rifater<span class="Sup">®</span>, Rifamate<span class="Sup">®</span>, Rimactane<span class="Sup">®</span>), rifapentine (Priftin<span class="Sup">®</span>)</li>
<li>a benzodiazepine to treat trouble with sleeping and/or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>-diazepam (Diastat<span class="Sup">®</span>, Valium<span class="Sup">®</span>)</li>
<li>a corticosteroid to treat <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>-dexamethasone (Decadron<span class="Sup">®</span>)</li>
<li>an HMG-CoA reductase inhibitor to lower <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels-atorvastatin (Caduet<span class="Sup">®</span>, Lipitor<span class="Sup">®</span>), fluvastatin (Lescol<span class="Sup">®</span>), lovastatin (Advicor<span class="Sup">®</span>, Altoprev<span class="Sup">®</span>, Mevacor<span class="Sup">®</span>), pitavastatin (Livalo<span class="Sup">®</span>), rosuvastatin (Crestor<span class="Sup">®</span>), simvastatin (Juvisync<span class="Sup">®</span>, Simcor<span class="Sup">®</span>, Vytorin<span class="Sup">®</span>, Zocor<span class="Sup">®</span>)</li>
<li>an immunosuppressant to prevent organ <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span>-cyclosporine (Gengraf<span class="Sup">®</span>, Sandimmune<span class="Sup">®</span>, Neoral<span class="Sup">®</span>), sirolimus (Rapamune<span class="Sup">®</span>), tacrolimus (Prograf<span class="Sup">®</span>)</li>
<li>a medicine to treat narcotic withdrawal and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>-buprenorphine (Buprenex<span class="Sup">®</span>, Butrans<span class="Sup">®</span>, Subutex<span class="Sup">®</span>), buprenorphine/naloxone (Suboxone<span class="Sup">®</span>), methadone (Dolophine<span class="Sup">®</span>, Methadose<span class="Sup">®</span>)</li>
<li>a PDE-5 inhibitor to treat <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> and/or <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>-sildenafil (Revatio<span class="Sup">®</span>, Viagra<span class="Sup">®</span>), tadalafil (Adcirca<span class="Sup">®</span>, Cialis<span class="Sup">®</span>), vardenafil (Levitra<span class="Sup">®</span>, Staxyn<span class="Sup">™</span>)</li>
<li>a platelet aggregation inhibitor to prevent blood clots-clopidogrel (Plavix<span class="Sup">®</span>)</li>
</ul>
<p><span class="Bold">Ask your doctor or pharmacist if you are not sure if your medicine is one that is listed above.</span></p>
<p><span class="Bold">Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.</span></p>
<p>Your doctor and your pharmacist can tell you if you can take these medicines with INTELENCE<span class="Sup">®</span>. Do not start any new medicines while you are taking INTELENCE<span class="Sup">®</span> without first talking with your doctor or pharmacist. You can ask your doctor or pharmacist for a list of medicines that can interact with INTELENCE<span class="Sup">®</span>.</p>
<p><span class="Bold">How should I take INTELENCE<span class="Sup">®</span>?</span></p>
<ul>
<li><span class="Bold">Stay under the care of your doctor during treatment with INTELENCE<span class="Sup">®</span>.</span></li>
<li><span class="Bold">Take INTELENCE<span class="Sup">®</span> tablets every day exactly as prescribed by your doctor.</span></li>
<li>Your doctor will tell you how many INTELENCE<span class="Sup">®</span> tablets to take and when to take them. Talk to your doctor if you have questions about when to take INTELENCE<span class="Sup">®</span>.</li>
<li>INTELENCE<span class="Sup">®</span> is taken two times each day.<dl>
<dt>-</dt>
<dd>If your child takes INTELENCE<span class="Sup">®</span>, your doctor will prescribe the right dose based on your child's weight.</dd>
</dl>
</li>
<li>
<span class="Bold">Always take INTELENCE<span class="Sup">®</span> following a meal</span>. Do not take INTELENCE<span class="Sup">®</span> on an empty stomach. INTELENCE<span class="Sup">®</span> may not work as well if you take it on an empty stomach.</li>
<li>Do not change your dose or stop taking INTELENCE<span class="Sup">®</span> without first talking with your doctor. See your doctor regularly while taking INTELENCE<span class="Sup">®</span>.</li>
<li>Swallow INTELENCE<span class="Sup">®</span> whole, with a glass of water. Do not chew the tablet(s).</li>
<li>If you are unable to swallow INTELENCE<span class="Sup">®</span> tablets whole, you may take your dose of INTELENCE<span class="Sup">®</span> as follows:<dl>
<dt> </dt>
<dd>Step 1: Measure approximately 5 mL (1 teaspoon) of water and pour into a cup.</dd>
<dt> </dt>
<dd>Step 2: Place the tablets in the cup containing 5 mL of water. If needed, add more water to cover the tablets. <span class="Bold">Do not put the tablets in other liquids.</span>
</dd>
<dt> </dt>
<dd>Step 3: Stir well until the water looks milky.</dd>
<dt> </dt>
<dd>Step 4: At this step, you may add a small amount of water, orange juice or milk to make it easier to take.</dd>
<dt> </dt>
<dd>Step 5: Drink right away.</dd>
<dt> </dt>
<dd>Step 6: Add more water, orange juice or milk to the cup to rinse the cup several times and completely swallow each time to make sure you take your entire dose of INTELENCE<span class="Sup">®</span>.</dd>
</dl>
</li>
<li>Avoid using grapefruit juice or warm (more than 104°F or 40°C) or carbonated beverages when taking INTELENCE<span class="Sup">®</span> tablets.</li>
<li>When your supply of INTELENCE<span class="Sup">®</span> starts to run low, get more from your doctor or pharmacy. It is important not to run out of INTELENCE<span class="Sup">®</span>. The amount of HIV in your blood may increase if the medicine is stopped even for a short time.</li>
<li>If you miss a dose of INTELENCE<span class="Sup">®</span> within 6 hours of the time you usually take it, take your dose of INTELENCE<span class="Sup">®</span> following a meal as soon as possible. Then, take your next dose of INTELENCE<span class="Sup">®</span> at the regularly scheduled time. If you miss a dose of INTELENCE<span class="Sup">®</span> by more than 6 hours of the time you usually take it, wait and then take the next dose of INTELENCE<span class="Sup">®</span> at the regularly scheduled time.</li>
<li>Do not take more than your prescribed dose to make up for a missed dose.</li>
<li>If you take too much INTELENCE<span class="Sup">®</span>, contact your local poison control center or go to the nearest emergency room right away.</li>
</ul>
<p><span class="Bold">What are the possible side effects of INTELENCE<span class="Sup">®</span>?</span></p>
<p><span class="Bold">INTELENCE<span class="Sup">®</span> can cause serious side effects including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> is a common side effect of INTELENCE<span class="Sup">®</span>. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> can be serious. Call your doctor right away if you get a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In some cases, severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may need to be treated in a hospital and may potentially lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.<br><span class="Bold">If you get a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with any of the following symptoms, stop taking INTELENCE<span class="Sup">®</span> and call your doctor or get medical help right away:</span><ul>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> or sores in your mouth, or your skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> and peels</li>
<li>trouble swallowing or breathing</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, eyes, lips, tongue, or throat</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, yellowing of the skin or whites of the eyes, dark urine, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on the right side of the stomach-area (<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>).</li>
</ul>
</li>
<li>
<span class="Bold">Changes in body fat</span> can happen in people taking HIV medicines. These changes may include an increased amount of fat in the upper back and neck ("<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>"), breast, and around the middle of your body (trunk). Loss of fat from the legs, arms, and face may also happen. The exact cause and long-term health effects of these problems are not known.</li>
<li>
<span class="Bold">Changes in your immune   system (<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span>)</span> can happen when you start   taking HIV medicines. Your immune system may get stronger and begin to   fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that have been hidden in your body for a long time. Call   your doctor right away if you start having any new symptoms after starting   your HIV medicine.</li>
</ul>
<p>In adults, common side effects of INTELENCE<span class="Sup">®</span> include <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the hands or feet.</p>
<p>In children, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is a common side effect of INTELENCE<span class="Sup">®</span>.</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects with INTELENCE<span class="Sup">®</span>. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store INTELENCE<span class="Sup">®</span>?</span></p>
<ul class="Disc">
<li>Store INTELENCE<span class="Sup">®</span>   tablets at 59°F to 86°F (15°C to 30°C).</li>
<li>Keep INTELENCE<span class="Sup">®</span> in the original bottle given to you by your pharmacist. After opening, keep the bottle tightly closed to protect INTELENCE<span class="Sup">®</span> from moisture.</li>
<li>The INTELENCE<span class="Sup">®</span> bottle contains a desiccant packet to help keep your medicine dry (protect it from moisture). The bottle of 25 mg tablets contains 2 desiccant packets. The bottles of 100 mg and 200 mg tablets contain 3 desiccant packets. Keep the desiccant packets in the bottle. <span class="Bold">Do not eat the desiccant packets.</span>
</li>
</ul>
<p><span class="Bold">Keep INTELENCE<span class="Sup">®</span> and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about INTELENCE<span class="Sup">®</span></span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use INTELENCE<span class="Sup">®</span> for a condition for which it was not prescribed. Do not give INTELENCE<span class="Sup">®</span> to other people even if they have the same condition you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about INTELENCE<span class="Sup">®</span>. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about INTELENCE<span class="Sup">®</span> that is written for health professionals. For more information, you may also call Janssen Products, LP at 1-800-526-7736.</p>
<p><span class="Bold">What are the ingredients in INTELENCE<span class="Sup">®</span>?</span></p>
<p><span class="Bold">Active ingredient:</span> etravirine.</p>
<p><span class="Bold">25 mg and 100 mg INTELENCE<span class="Sup">®</span> tablets contain the following inactive ingredients:</span> hypromellose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate and lactose monohydrate</p>
<p><span class="Bold">200 mg INTELENCE<span class="Sup">®</span> tablets contain the following inactive ingredients:</span> hypromellose, silicified microcrystalline cellulose, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium and magnesium stearate.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<p class="First">Product of Belgium<br>Finished Product Manufactured by:<br>Janssen Cilag S.p.A., Latina, IT<br>Manufactured for:<br>Janssen Therapeutics, Division of Janssen Products, LP, Titusville NJ 08560</p>
<p>INTELENCE<span class="Sup">®</span> is the registered trademark of Tibotec Pharmaceuticals.</p>
<p>Revised August 2012</p>
<p>© Janssen Pharmaceuticals, Inc. 2008</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label</span></p>
<p><span class="Bold">120 Tablets<br>NDC 54868-5864-0</span></p>
<p><span class="Bold">INTELENCE<span class="Sup">®</span><br><span class="Italics">(etravirine) tablets</span></span></p>
<p><span class="Bold">100 mg</span></p>
<p>Each tablet contains<br>100 mg of etravirine.</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73667241-b95a-49b0-9c51-a4289f20d5c2&amp;name=5864.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 200 mg Bottle Label</span></p>
<p><span class="Bold">60 Tablets<br>                     NDC 54868-6368-0</span></p>
<p><span class="Bold">INTELENCE<span class="Sup">®</span><br><span class="Italics">(etravirine) tablets</span></span></p>
<p><span class="Bold">200 mg</span></p>
<p>Each tablet contains<br>200 mg of etravirine.</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 200 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73667241-b95a-49b0-9c51-a4289f20d5c2&amp;name=6368.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INTELENCE 		
					</strong><br><span class="contentTableReg">etravirine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5864(NDC:59676-570)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>etravirine</strong> (etravirine) </td>
<td class="formItem">etravirine</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TMC125;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5864-0</td>
<td class="formItem">120  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022187</td>
<td class="formItem">02/21/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INTELENCE 		
					</strong><br><span class="contentTableReg">etravirine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6368(NDC:59676-571)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>etravirine</strong> (etravirine) </td>
<td class="formItem">etravirine</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex, oblong) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T200</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6368-0</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022187</td>
<td class="formItem">10/10/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-5864, 54868-6368)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>26d15de0-e8b5-4f82-9c43-624f7f510a6a</div>
<div>Set id: 73667241-b95a-49b0-9c51-a4289f20d5c2</div>
<div>Version: 2</div>
<div>Effective Time: 20130102</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
